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Chapter I: 
Introduction 
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In his studies of the neuromuscular junction in 1851, Claude Bernard discovered 
that signals could be transmitted between cells by chemicals that we now call 
neurotransmitters. He demonstrated that curare, a toxin isolated from plants used to make 
arrow toxins for hunting, could block this transmission in a reversible manner. Today, we 
know that curare acts as a competitive antagonist to acetylcholine blocking 
neurotransmission at the nerve-muscle junction and causing paralysis. Nicotine binds and 
activates several of these receptor types, which are therefore called the nicotinic 
acetylcholine receptors (nAChRs). Over the past 25 years, a great deal of progress has been 
made towards understanding both the molecular and biophysical properties of nAChRs, as 
well as their relevance towards important biological processes in the brain.  
 
The nicotinic acetylcholine receptors 
The nAChRs are pentameric, ligand-gated ion channels. Their endogenous ligand, 
acetylcholine, as well as pharmacological agents such as nicotine, activate the channels. 
The specific proteins that make up the receptors for acetylcholine have been identified, 
cloned, and several can be expressed in heterologous systems such as Xenopus laevis 
oocytes or human embryonic kidney (HEK) cells. Heterologous expression enables the use 
of electrophysiology and microscopy to conduct precise pharmacological and biophysical 
experiments, several of which are described in this thesis.  
Neuronal nAChRs are expressed throughout the central and peripheral nervous 
system, and are made up of nine different α subunits and three different β subunits in both 
heteropentameric and homopentameric combinations such as α4β2 and α7, respectively. 
Different subtypes have sensitivities to ACh that vary over 3-4 orders of magnitude. The 
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most widely expressed receptor, α4β2, has two stoichiometries: (α4)2(β2)3 and (α4)3(β2)2, 
with ACh sensitivities of approximately 1 µM and 80 µM, respectively. Gating of the 
channel results in permeability to Na+, K+, and, for some receptor subtypes, Ca2+. In 
general, activation of nAChRs in the brain regulates the amount of other neurotrasmitters 
realeased into synaptic clefts, including dopamine, serotonin, GABA, and glutamate. Thus, 
nAChRs can be thought of as commonly functioning as performing a tuning function, or 
“volume knob” for other neurotransmitter systems.  
Most nAChRs in the brain are expressed at presynaptic terminals (Gotti et al., 
2006), where they are able to modulate neurotransmitter release. ACh is released into the 
synaptic cleft and then rapidly degraded by GPI-anchored acetylcholinesterase (AChE) 
enzymes. While ACh is present, it binds to nAChRs causing activation and gating, but 
prolonged exposure results in desensitization, a closed channel state with ACh (or another 
ligand) bound, that is more stable than the open channel conformation.  
Nicotinic receptors are also found on the somatodendritic areas of the plasma 
membrane, which led to the volume transmission hypothesis that ACh that has escaped 
degradation within the synaptic cleft can diffuse out toward neuronal cell bodies, binding 
and activating receptors there. For this to happen, enough ACh would have to escape 
degradation, and likely more sensitive receptors would have to be expressed on the 
somatodendritic compartment. Another effect of somatodendritic localization of receptors 
could be activation by other endogenous ligands that are not degraded rapidly, namely 
choline, which activates α7.  
 
The molecular structure of nAChRs 
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Unwin and colleagues performed electron microscopic reconstruction, at increasing 
resolution, of the muscle-type nAChR receptor over ~3 decades, using samples derived 
from the postsynaptic membranes of the Torpedo ray electric organ (Miyazawa et al., 2003; 
Unwin, 2005). The Torpedo electric organ has been a useful model system due to its high 
concentration of ACh receptors and relative ease of isolation from the animal. The papers 
in 2003 and 2005 revealed a barrel-structured cylinder with a diameter of ~8 nm and length 
of ~16 nm, organized as a pentamer of subunits arranged around a central pore, that can be 
divided into extracellular (ECD), transmembrane (TMD), and intracellular (ICD) domains. 
The TMD is composed of 4 membrane-spanning α-helices, with the second (TM2) 
arranged so that it lines the water-filled pore of the channel. TM1, 3, and 4 lie outside the 
pore, and contact the membrane, providing an opportunity for the lipid composition of local 
membrane to interact with and possibly influence the gating properties of the channel.  
Within the membrane, the pore-lining TM domains have open and closed 
configurations or differing levels of stability. These biophysical properties of the pore 
region determine the activation and desensitization kinetics of the channel, which vary 
widely across nAChR subtypes. When the channel is closed, the TM2 helices are shifted 
inward, blocking the passage of ions across the membrane. Upon activation by a ligand, the 
TM2 helices shift away from the center, allowing ions to pass through. However, the closed 
state is more stable than the open state when ligand is bound, which leads to a desensitized 
state with ligand bound and the channel closed. Most ligand-gated ion channels likely share 
this allosteric mechanism.  
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The cytoplasmic domain or ICD of nAChRs consists mostly of a connecting loop 
between the TM3 and TM4 domains. This loop varies greatly between subunits both is 
sequence and in length. The cytoplasmic loop has several functions that govern properties 
of the channel. The muscle subunits have several phosphorylation sites that control receptor 
desensitization (Swope et al., 1995), and the β2 subunit interacts with several cytoskeletal 
proteins including dynamin, tubulin, and clathrin, in addition to interacting with GPCR 
systems (Kabbani, 2008). Targeting the intracellular domain might be fruitful for drug 
discovery due to the diversity between subunits, and thus opportunity to achieve selectivity 
between them. To do this successfully, much more work is needed to determine how 
modifications to the intracellular loops might impact both the biophysics of the channel and 
the consequences on the downstream biology. 
The crystal structure of the snail, Lymnaea stagnalis, acetylcholine-binding protein 
(AChBP) was solved in 2001, and provided a basis for the structure of the ligand-binding 
ECD of the nAChR (Hansen et al., 2006). AChBP is a soluble pentamer that binds up to 5 
ACh molecules at the interfaces between subunits. In support of the use of AChBP as a 
model for the ECD, it also binds to nicotine, curare, and α-bungarotoxin, and is likely most 
closely related to the α subunits of the nAChRs (Hansen et al., 2006), and has been used 
widely as a tool for screening of drug candidates targeting nicotinic receptors. Each subunit 
folds into a β-sheet sandwich composed of 6 inner sheets and 4 outer sheets. The ECD 
confers the differential selectivity of ligands. A deeper understanding of how ligands 
interact with the ECD at both the orthosteric sites (competitive with ACh) and allosteric 
sites (non-competitive with ACh) is required to design ligands and drugs that selectively 
target some nAChR subtypes over others.  
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The biological importance of nAChRs 
The cholinergic system is important in a wide variety of neuronal and cognitive 
processes, including addiction and reward (Tang and Dani, 2009), cognition (Levin, 2002), 
mood (Picciotto et al., 2008), pain (Decker et al., 2001), and possibly neuroprotection from 
disease (Hernan et al., 2002). Here, I provide a brief review of some of the current 
controversies relating to the applicability of nAChR biology to these processes.  
 
Addiction and reward 
While approximately 40% of smokers attempt to quit in a given year, only 10% of 
those who attempt will successfully abstain for a full year (Gonzales et al., 2006). Smoking 
is a leading cause of preventable death, and pharmacotherapies to increase quitting success 
rates would be highly valuable for public health. An enormous amount of progress has been 
made over the past decade in elucidating the specific brain regions and receptors 
responsible for nicotine addiction. This led to the rational design and FDA approval of 
varenicline, a novel drug for smoking cessation. Although quitting success rates for patients 
taking varenicline were double those for placebo, the overall quit rate was modest at around 
9% across many studies (Cahill et al., 2013).  
Nicotine induces long-term potentiation (LTP) in a dose-dependent manner through 
increased dopamine release in the ventral tegmental area (VTA) (Mansvelder and 
McGehee, 2000). This process is likely the underlying mechanism for nicotine’s ability to 
both cause pleasure in the mesolimbic dopamine “pleasure” circuitry, and also to induce 
long lasting changes in connections between neurons that comprise the learning process of 
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becoming addicted. This mechanism is likely a general one that may apply to all addictive 
drugs, and even other addictions such as food and other behavioral addictions. Indeed, 
activation of dopaminergic neurons in the VTA occurs with all well-studied drugs of abuse 
(Leslie et al., 2013).  
Two predominant pharmacological strategies for treatment of nicotine addiction to 
decrease the rate of patients returning to smoking have emerged. The first is to decrease 
signaling through β2* nAChRs in the VTA. This strategy is supported by experiments done 
using knock-out mice and by the clinical success, although modest, of varenicline. The 
second strategy is to increase signaling through α5* nAChRs in the MHb, which mediate 
the aversive reaction to higher doses of nicotine.  
Several types of nAChR subunits are expressed in the VTA, including β2, α4, and 
α6. Knock-out (KO) mice have been made for each of these subunits, and the knocked-out 
subunits can be selectively re-expressed in specific brain regions. Nicotine self-
administration experiments have shown that β2-KO, α4-KO, and α6-KO mice do not 
respond to nicotine, but that selective re-expression in the VTA of the knocked out subunit 
regain nicotine self-administration behavior (Pons et al., 2008). These experiments provide 
excellent evidence that all three subunits may be required in the VTA for nicotine 
addiction, and suggest that pharmacological inhibition of the signal through these receptors 
could be useful as a smoking cessation aid.  
Three distinct classes of drugs could be utilized to achieve this outcome: 
antagonists that selectively block channel opening, partial agonists that activate the channel 
with lower efficacy than endogenous ACh or nicotine, of negative allosteric modulators  
(NAMs) that lower the efficacy or increase the potency of ACh/nicotine. The most favored 
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strategy is to use a partial agonist because they may work via two distinct mechanisms. 
First, they activate the channel at a lower level than endogenous ACh or nicotine, but may 
cause enough dopamine release to mitigate the sensations of craving and withdrawal. 
Second, partial agonists may reduce the acute positive sensations of smoking nicotine by 
acting as an antagonist when other agonists with greater efficacy (nicotine) are present. 
Varenicline is a weak partial agonist on α4β2, with a relative efficacy of <15% compared to 
nicotine or ACh, Antagonists or NAMs would theoretically achieve the second mechanism 
of decreasing the reward received from nicotine administration, but would not replicate the 
low-level dopamine release of partial agonists, and therefore are less likely to reduce 
craving and withdrawal symptoms.  
While a partial agonist strategy on α4β2 or α6α4β2 in the VTA appears to be 
promising for nicotine addiction, and varenicline, an α4β2 partial agonist with ~13% 
efficacy compared to ACh, has been tested extensively in humans and even approved by 
the FDA, its efficacy is modest, with less than ten percent of patients abstaining from 
smoking for one year. Varenicline may also be a partial agonist on α6α4β2, but we have 
less certainty because of challenges regarding functional expression of α6* nAChRs.  
The second strategy is to increase signal from α5* nAChRs in the medial habenula 
(MHb), which mediate the aversive stimulus of higher doses of nicotine. The α5D398N 
variant is associated with higher rates of nicotine addiction in humans, and inclusion of the 
398N variant exhibits reduced receptor function in vitro (Bierut et al., 2008). Experiments 
in α5-KO mice have demonstrated that removal of α5 results in the loss of aversion to high 
doses of nicotine (Fowler et al., 2011). Additionally, re-expression of α5 in the MHb 
restores aversion to nicotine.  
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Taken together, these experiments provide a strong rationale for the development 
of an α5 positive allosteric modulator (PAM) to increase the aversive stimulus received 
from nicotine. A similar aversion therapy strategy is currently employed to treat severe 
alcohol abuse using the drug Antabuse (disulfuram) as conditional emetic. Disulfiram 
produces an acute emetic response when combined with alcohol, creating a strong deterrent 
to consumption, especially after the effects are experienced once. One major limitation is 
that patients realize that the drug is causing the emetic effects, and therefore plan to stop 
taking the drug and resume alcohol consumption. Frequently, patients are placed on a 
program whereby another person must watch the addict take the pill each day, with visual 
confirmation that the pill has been swallowed. Although burdensome, a similar method 
could be implemented with patients addicted to nicotine.  
 
Cognition and schizophrenia 
The symptoms of schizophrenia can be divided into three categories: positive, 
negative, and cognitive. The positive symptoms are psychotic in nature, consisting of 
hallucinations and delusions. The negative symptoms are primarily flat affect, anhedonia, 
and depression, while the cognitive symptoms involve deficits in working memory, 
attention, and executive functioning. The negative and cognitive symptoms often precede 
positive symptom onset (Addington and Addington, 1993), and persist even after the 
positive symptoms have been treated successfully by commonly used antipsychotics, which 
alleviate positive symptoms in the majority of patients(Erhart et al., 2006).  
All clinically effective antipsychotics used to treat the positive symptoms of 
schizophrenia have diverse and complex polypharmacology; each individual drug has 
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activity on a wide range of targets in the CNS (Roth et al., 2004). One commonality 
between these drugs is that they all act as either an antagonist or a partial agonist on the 
dopamine D2 receptor. This common mechanism is widely accepted as the mechanism by 
which they exert their effect on the positive symptoms of schizophrenia(Seeman, 2002). 
While effective therapies may light the way for development of better treatment of 
positive symptoms, that luxury does not exist for the negative and cognitive symptoms of 
schizophrenia. The α7 nAChR has become a widely investigated target for treatment of the 
cognitive and negative domains due to evidence from both in vivo experiments and human 
clinical data. Initially, it was found that α7 antagonists could induce sensory gating deficits 
in auditory evoked potential responses (Luntz-Leybman et al., 1992), consistent with 
similar gating deficits in schizophrenics, and later in genetic mouse models of 
schizophrenia (Lipska and Weinberger, 2000). Additionally, post-mortem studies of human 
brains revealed a los of α7 nAChRs in schizophrenic patients (Freedman et al., 1995), 
supporting a hypothesis that increasing signal through α7 may restore a pre-existing deficit 
in schizophrenics.  
Interpretation of auditory gating experiments is complicated by the fact that some 
non-schizophrenic patients (2-5% of the population) display deficits in gating but no 
symptoms of schizophrenia. Interestingly, several drugs, including nicotine, have 
demonstrated the ability to normalize sensory gating abnormalities, but have not had a large 
effect on clinically detectable endpoints associated with measures of negative or cognitive 
symptoms. However, an overwhelming majority of schizophrenics smoke (>90%), and 
they tend to extract more nicotine per puff than normal patients (Williams et al., 2005), 
which is viewed as evidence of self-medication with nicotine.   
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Several agonists an partial agonists have been tested recently in clinical trials, and 
although some rescued sensory gating and showed initial signs of improvement in the form 
of increased attention and working memory (Gault et al., 2013; Lieberman et al., 2013), the 
results were judged to not warrant further development for both TC-5619 and ABT-126. 
Another compound, EVP-6124 may act by potentiating the endogenous response of 
α7 to ACh, as opposed to activating or desensitizing the channel. Interestingly, EVP-6124 
appears to potentiate the receptor at a concentration of 2 nM, which is below concentrations 
required for appreciable activation (Prickaerts et al., 2012). If this mechanism is 
responsible for the pro-cognitive effects seen in early-stage clinical trials, PAMs may 
provide an attractive modality to achieve a stronger therapeutic effect while reducing the 
confounding effects of activation and/or desensitization.  
Thus far, PAMs have not been investigated thoroughly due to possible toxicities 
associated with type II PAMs, and the lack of available molecules that act as type I PAMs. 
PAMs are defined by their ability to increase current magnitude, receptor sensitivity, and 
Hill coefficients by binding at an allosteric site on the receptor. Type I PAMs achieve this 
with little or no effect on the response waveform in terms of channel open time or 
desensitization kinetics. Type II PAMs, on the other hand, do slow desensitization kinetics, 
and may cause desensitized to channels to return to an active state as well, while ligand is 
bound (Williams et al., 2011).  
Two major concerns with type II PAMs predominate. First, the alteration of the 
response waveform, and thus the kinetics of calcium influx into the cell, may change the 
quality of information transmitted to the receiving cell, and the downstream signaling 
milieu. Second, large increases in intracellular calcium are associated with excitotoxicity 
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and cell death (Williams et al., 2012). Although some studies have found that type II 
PAMs can be used effectively on rat neurons in vitro without excitoxicity (Hu et al., 2009), 
rat neurons may be heartier than those from a mouse or human, and toxicity concerns will 
predominate when moving into the clinic in elderly Alzheimer’s patients whose neurons 
may be more vulnerable to increased intracellular calcium.  
For the reasons above, type I PAMs may be an attractive way of testing the 
hypothesis that increasing signal through α7 could be therapeutically valuable. Type I 
PAMs have been challenging to create from a medicinal chemistry perspective because 
most HTS technologies are unable to detect them due to the rapid desensitization kinetics 
of α7. Recently, several type II PAMs have been found, and a couple are in the process of 
entering the clinic (Pandya and Yakel, 2013). Some of these compounds may also have 
activity on other receptors, such as GABA or 5HT3, so a pure interpretation of their actions 
on α7 leading to improvements in cognitive function may not be possible.  
 
Mood 
Individuals with major depressive disorder (MDD) have higher rates of nicotine 
dependence (50-60%) than the general population (25%) (Glassman et al., 1990). 
Furthermore, in MDD patients, quitting smoking can exacerbate depressive symptoms 
leading to serious major depression. Other clinical studies have demonstrated an anti-
depressant effect of nicotine patches in non-smoker MDD patients (SalÃn-Pascual et al., 
1996), and at least two marketed anti-depressants have demonstrated efficacy for smoking 
cessation: buproprion (Hurt et al., 1997) and nortriptyline (Hall et al., 1998). Because 
nicotine, and all known nAChR agonists cause both activation and desensitization of the 
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receptor, it is difficult to separate the two in order to attribute any observed effect to one 
of the other.  Chronic nicotine also upregulates the amount of nAChRs on the plasma 
membrane (Buisson and Bertrand, 2001), further complicating interpretation of longer term 
use.   
The Flinders Sensitive Line (FSL) of rats provided strong support for the 
hypothesis that increased cholinergic tone can be involved in mood disorders, including 
depression (Mineur et al., 2011). FSL rats were bred for increased sensitivity to an 
acetylcholinesterase drug, diisopropylfluorophosphonate (DFP), resulting in abnormally 
high levels of ACh, and chronically increased cholinergic tone when exposed to the drug 
(Overstreet and Russell, 1982). FSL rats display several behavioral phenotypes associated 
with depression including increased anhedonia (Pucilowski et al., 1993), and reduced 
locomotor activity, weight and REM sleep (Overstreet, 1993). Furthermore, chronic stress 
(induced via inescapable foot shock plates or swim stress tests) can also induce 
supersensitivity of the cholinergic system in rats (Dilsaver et al., 1986). Taken together, the 
preclinical rational for increased cholinergic tone playing a role in depressive behavior is 
strong.  
If desensitization, and reduction of signal through nAChRs, is the mechanism by 
which nicotinic agonists could exert an anti-depressant effect, then we might expect an 
antagonist to reproduce the effect. The S-(+)-enantiomer of mecamylamine (TC-5214) was 
developed for the treatment of MDD (Rabenstein et al., 2006), and although results were 
promising both pre-clinically (Lippiello et al., 2008), and in an early phase 2 trial (Dunbar, 
2010), they were not successfully repeated and development has been discontinued, casting 
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doubt on the hypothesis that the reduced signal aspect of desensitization is the sole 
mechanism whereby cholinergic ligands might treat depression.  
 
nAChR agonists for analgesia 
Since the 1930’s we have known that nicotine acts as relatively weak analgesic, but 
little attention was paid to development of nAChR agonists as pain therapeutics until the 
discovery of epibatidine in 1976 by John Daly. Epibatidine is a potent nAChR agonist, with 
structural similarities to nicotine (Fig 1-1), isolated from the skin of the Ecuadorean 
poisonous dart frog species Epipedobates tricolor. Several factors prevented researchers 
from obtaining large enough amounts of the drug to perform experiments, including the 
endangered status of the animal, its inability to synthesize the molecule in captivity (on its 
own without consuming it from prey), and the lack of analytical tools to identify the 
specific compound from the frog’s skin that produced the effect.  
Eventually, the invention of nuclear magnetic resonance (NMR) spectroscopy 
enabled the discovery of the structure of epibatidine (Spande et al., 1992), leading to 
synthetic production of the compound in large quantities (Corey et al., 1993).  
Epibatidine’s use as a drug is limited by significant on-target toxicity with a small 
therapeutic window; the efficacious dose is very close to a lethal one. However, because 
epibatidine acts as a broad agonist on many nAChR subtypes, the possibility for more 
selective agonism was promising for a potential analgesic. Several nAChR agonists were 
developed that demonstrated improved safety profiles with retained anti-nociceptive 
activity in preclinical models. One such ligand, ABT-594, demonstrated similar potency on 
α4β2, but >1,000 fold less activity on muscular ACh receptors (Kesingland et al., 2000), 
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was developed through phase 2 trials, but discontinued due to gastrointestinal side 
effects, and possibly others. Nicotinic agonists have demonstrated efficacy at analgesia, and 
remain promising targets due to potential advantages over opioids through greater efficacy 
by more potent inhibition of pain and lack of tolerance, and lack of common opioid-related 
side effects including respiratory depression, cognitive impairment, dependency, and 
withdrawal. Thus far, separating the desirable anti-nociceptive effects from intolerable side 
effects has proven elusive. 
 
Figure 1-1. Structures of nicotine, epibatidine, and ABT-594.  
Nicotine and neuroprotection from disease 
Nicotine usage by smoking cigarettes may exert neuroprotective effects against 
developing Parkinson’s disease (PD) and Alzheimer’s disease. Thus far, the evidence is 
stronger for PD protection. Data from retrospective epidemiological studies demonstrates 
that compared to never smokers, smokers have a lower risk of developing PD by a factor of 
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0.39 (a 61% reduction in risk) for current smokers, and 0.80 for past smokers (Hernan et 
al., 2002). A similar retrospective analysis conducted on pairs of twins, wherein at least one 
twin had PD, demonstrated that those without PD tended to smoke an average of 9.8 pack 
years more than the PD twin (p=0.026) (Tanner et al., 2002). The design of this twin study 
makes it unlikely that either genetic or environmental factors confound the signal of lower 
risk of PD among smoker.  
One competing hypothesis is that early, undetected PD onset may cause a patient to 
quit smoking, perhaps by making it less rewarding due to disruption of the midbrain 
dopaminergic system. However, similar associations were found when smoking dosage 
was calculated only until 10 years before clinical onset of PD, suggesting that undetected 
PD onset is less likely to cause a patient to stop smoking, thus accounting for the 
association. These results are consistent with an interpretation that smoking exerts a 
neuroprotective effect on PD, but an early prodromal effect diminishing smoking behavior 
cannot be ruled out definitively. Furthermore, although evidence for the neuroprotective 
effect of smoking is substantial, more experiments are necessary to determine if nicotine 
alone, as opposed to smoking, can exert a similar effect.  
 
Drugs targeting nAChRs 
Although pharmacological targeting of nAChRs holds promise for a wide range of 
conditions, the FDA has approved few drugs targeting this mechanism. Nicotine itself is 
approved for smoking cessation as nicotine replacement therapy. Varenicline is also 
approved for smoking cessation. Cytisine is approved for the same indication in some 
European countries. Mecamylamine, an nAChR antagonist, was approved and marketed in 
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the 1950s for hypertension, but was discontinued due to side effects resulting from non-
specific blockage of nAChRs in the ganglionic system, causing inhibition of both the 
sympathetic and parasympathetic nervous system. Finally, buproprion is also approved for 
smoking cessation, but in addition to acting as an antagonist on nAChRs, inhibits the 
dopamine and norepinephrine transporters.  
The diversity of nAChRs subtypes and differential expression in different brain 
regions provides a plausible rationale by which a pharmacological agent could achieve 
specificity and perhaps treat a condition with few side effects. A deeper understanding of 
the composition of the various subtypes, where they are expressed both on the plasma 
membrane of the cell and in which neuronal subtypes, and how the biophysical structures 
interact with specific ligands is critical to design therapeutics targeting the neuronal 
cholinergic system.  
The nAChR subtype studied in this thesis is α4β2, which is the most abundant 
receptor in the human brain. Experiments on heterologously expressed receptors in oocytes 
demonstrated that varying the ratio of α4:β2 RNA injected into the oocyte could change the 
electrophysiological properties of the resulting receptors (Zwart and Vijverberg, 1998). 
This is due to the presence of two stoichiometries: a lower sensitivity (α4)3(β2)2, and a 
higher sensitivity (α4)3(β2)2 receptor (Fig 1-2). 
 Higher sensitivity Lower sensitivity 
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Figure 1-2. The two stoichiometries of the α4β2 nAChR receptor. 
The discovery of lynx1 
The lynx1 protein is a member of the ly-6/PLAUER superfamily, and expressed 
throughout the mammalian brain and peripheral nervous system (Miwa et al., 1999). It 
shares structural homology with snake venom toxins such as α-bungarotoxin, but is GPI-
anchored. Addition of lynx1 to heterologously expressed α4β2 results in decreased 
sensitivity to ACh, while lynx1-KO mice display hypersensitivity to nicotine and improved 
learning and memory (Miwa et al., 2006). Data published thus far are consistent with a 
mechanism of lynx1 that would be expected of a GPI-anchored competitive antagonist 
binding to nAChRs at the plasma membrane (Miwa et al., 2011), depicted in Figure 1-3. 
Chapter two of this thesis develops the hypothesis that lynx1 might act intracellularly, in 
the endoplasmic reticulum, to influence the assembly of the α4β2 nAChR, thereby biasing 
the stoichiometry of the population of receptors reaching the plasma membrane. 
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Figure 1-3. A model of lynx1 binding to a nAChR on the plasma membrane at the agonist-
binding site. 
Epilepsy and ADNFLE 
Epilepsy is defined as having multiple incidences of seizure, and affects 1-2% of 
the population. While epilepsy is generally thought to result from hypersynchrony of neural 
firing, individual patients likely have differing pathophysiology and brain regions affected. 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a rare monogenic form 
of epilepsy with a prevalence rate lower than 1 in 100,000. ADNFLE was the first form of 
epilepsy linked to genetic mutation in the nAChR α4 subunit (Steinlein et al., 1995). Since 
then, several other mutations in nAChR subunits have been associated with a high 
penetrance of ADNFLE. Chapter three of this thesis develops the hypothesis that at least 
one of the these mutations might cause ADNFLE by both increasing the sensitivity of 
α4β2, and altering the stoichiometry of α4β2 and α5α4β2 receptors on the plasma 
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membrane through biased assembly in the endoplasmic reticulum, and thus apparent in 
experiments on heterologous expression systems.  
 
  
 21 
References 
 
Addington, J., and Addington, D. (1993). Premorbid functioning, cognitive functioning, 
symptoms and outcome in schizophrenia. Journal of Psychiatry and Neuroscience 18, 18. 
Bierut, L.J., Stitzel, J.A., Wang, J.C., Hinrichs, A.L., Grucza, R.A., Xuei, X., Saccone, 
N.L., Saccone, S.F., Bertelsen, S., Fox, L., et al. (2008). Variants in nicotinic receptors and 
risk for nicotine dependence. Am J Psychiatry 165, 1163-1171. 
Buisson, B., and Bertrand, D. (2001). Chronic exposure to nicotine upregulates the human 
a4b2 nicotinic acetylcholine receptor function. J Neurosci 21, 1819-1829. 
Cahill, K., Stevens, S., Perera, R., and Lancaster, T. (2013). Pharmacological interventions 
for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst 
Rev 5. 
Corey, E., Loh, T.P., AchyuthaRao, S., Daley, D.C., and Sarshar, S. (1993). 
Stereocontrolled total synthesis of (+)-and (-)-epibatidine. The Journal of Organic 
Chemistry 58, 5600-5602. 
Decker, M.W., Meyer, M.D., and Sullivan, J.P. (2001). The therapeutic potential of 
nicotinic acetylcholine receptor agonists for pain control. Expert opinion on investigational 
drugs 10, 1819-1830. 
Dilsaver, S.C., Snider, R.M., and Alessi, N.E. (1986). Stress induces supersensitivity of a 
cholinergic system in rats. Biological psychiatry 21, 1093-1096. 
Dunbar, G. (2010). Positive effects of the nicotinic channel blocker TC-5214 as 
augmentation treatment in patients with major depressive disorder who are inadequate 
responders to a first-line SSRI. Paper presented at: Journal of Psychopharmacology (SAGE 
PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, 
ENGLAND). 
Erhart, S.M., Marder, S.R., and Carpenter, W.T. (2006). Treatment of schizophrenia 
negative symptoms: future prospects. Schizophrenia Bulletin 32, 234-237. 
Fowler, C.D., Lu, Q., Johnson, P.M., Marks, M.J., and Kenny, P.J. (2011). Habenular α5 
nicotinic receptor subunit signalling controls nicotine intake. Nature. 
Freedman, R., Hall, M., Adler, L.E., and Leonard, S. (1995). Evidence in postmortem brain 
tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. 
Biological psychiatry 38, 22-33. 
Gault, L., Ritchie, C., Robieson, W., Pritchett, Y., Othman, A., and Lenz, R. (2013). 
Efficacy and safety of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's 
dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 9, P138-
P138. 
 22 
Glassman, A.H., Helzer, J.E., Covey, L.S., Cottler, L.B., Stetner, F., Tipp, J.E., and 
Johnson, J. (1990). Smoking, smoking cessation, and major depression. Jama 264, 1546-
1549. 
Gonzales, D., Rennard, S.I., Nides, M., Oncken, C., Azoulay, S., Billing, C.B., Watsky, 
E.J., Gong, J., Williams, K.E., and Reeves, K.R. (2006). Varenicline, an a4b2 nicotinic 
acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for 
smoking cessation: a randomized controlled trial. JAMA 296, 47-55. 
Gotti, C., Zoli, M., and Clementi, F. (2006). Brain nicotinic acetylcholine receptors: native 
subtypes and their relevance. Trends Pharmacol Sci 27, 482-491. 
Hall, S.M., Reus, V.I., Munoz, R.F., Sees, K.L., Humfleet, G., Hartz, D.T., Frederick, S., 
and Triffleman, E. (1998). Nortriptyline and cognitive-behavioral therapy in the treatment 
of cigarette smoking. Archives of general psychiatry 55, 683-690. 
Hansen, S.B., Sulzenbacher, G., Huxford, T., Marchot, P., Bourne, Y., and Taylor, P. 
(2006). Structural characterization of agonist and antagonist-bound acetylcholine-binding 
protein from Aplysia californica. J Mol Neurosci 30, 101-102. 
Hernan, M.A., Takkouche, B., Caamano-Isorna, F., and Gestal-Otero, J.J. (2002). A meta-
analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann 
Neurol 52, 276-284. 
Hu, M., Gopalakrishnan, M., and Li, J. (2009). Positive allosteric modulation of α7 
neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat 
primary cortical neurons. British journal of pharmacology 158, 1857-1864. 
Hurt, R.D., Sachs, D.P., Glover, E.D., Offord, K.P., Johnston, J.A., Dale, L.C., Khayrallah, 
M.A., Schroeder, D.R., Glover, P.N., and Sullivan, C.R. (1997). A comparison of 
sustained-release bupropion and placebo for smoking cessation. New England Journal of 
Medicine 337, 1195-1202. 
Kabbani, N. (2008). Proteomics of membrane receptors and signaling. Proteomics 8, 4146-
4155. 
Kesingland, A., Gentry, C., Panesar, M., Bowes, M., Vernier, J.-M., Cube, R., Walker, K., 
and Urban, L. (2000). Analgesic profile of the nicotinic acetylcholine receptor agonists,(+)-
epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 
86, 113-118. 
Leslie, F.M., Mojica, C.Y., and Reynaga, D.D. (2013). Nicotinic receptors in addiction 
pathways. Molecular pharmacology 83, 753-758. 
Levin, E.D. (2002). Nicotinic receptor subtypes and cognitive function. J Neurobiol 53, 
633-640. 
 23 
Lieberman, J.A., Dunbar, G., Segreti, A.C., Girgis, R.R., Seoane, F., Beaver, J.S., Duan, 
N., and Hosford, D.A. (2013). A randomized exploratory trial of an alpha-7 nicotinic 
receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. 
Neuropsychopharmacology 38, 968-975. 
Lippiello, P.M., Beaver, J.S., Gatto, G.J., James, J.W., Jordan, K.G., Traina, V.M., Xie, J., 
and Bencherif, M. (2008). TC‐5214 (S‐(+)‐Mecamylamine): A Neuronal Nicotinic 
Receptor Modulator with Antidepressant Activity. CNS neuroscience & therapeutics 14, 
266-277. 
Lipska, B.K., and Weinberger, D.R. (2000). To model a psychiatric disorder in animals: 
schizophrenia as a reality test. Neuropsychopharmacology 23, 223-239. 
Luntz-Leybman, V., Bickford, P.C., and Freedman, R. (1992). Cholinergic gating of 
response to auditory stimuli in rat hippocampus. Brain Res 587, 130-136. 
Mansvelder, H.D., and McGehee, D.S. (2000). Long-term potentiation of excitatory inputs 
to brain reward areas by nicotine. Neuron 27, 349-357. 
Mineur, Y.S., Einstein, E.B., Seymour, P.A., Coe, J.W., O'Neill B, T., Rollema, H., and 
Picciotto, M.R. (2011). α4β2 nicotinic acetylcholine receptor partial agonists with low 
intrinsic efficacy have antidepressant-like properties. Behavioural pharmacology 22, 291-
299. 
Miwa, J.M., Freedman, R., and Lester, H.A. (2011). Neural systems governed by nicotinic 
acetylcholine receptors: emerging hypotheses. Neuron 70, 20-33. 
Miwa, J.M., Ibanez-Tallon, I., Crabtree, G.W., Sanchez, R., Sali, A., Role, L.W., and 
Heintz, N. (1999). lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine 
receptors in the mammalian CNS. Neuron 23, 105-114. 
Miwa, J.M., Stevens, T.R., King, S.L., Caldarone, B.J., Ibanez-Tallon, I., Xiao, C., 
Fitzsimonds, R.M., Pavlides, C., Lester, H.A., Picciotto, M.R., et al. (2006). The Prototoxin 
lynx1 Acts on Nicotinic Acetylcholine Receptors to Balance Neuronal Activity and 
Survival In Vivo. Neuron 51, 587-600. 
Miyazawa, A., Fujiyoshi, Y., and Unwin, N. (2003). Structure and gating mechanism of the 
acetylcholine receptor pore. Nature 423, 949-955. 
Overstreet, D., and Russell, R. (1982). Selective breeding for diisopropyl fluorophosphate-
sensitivity: behavioural effects of cholinergic agonists and antagonists. 
Psychopharmacology 78, 150-155. 
Overstreet, D.H. (1993). The Flinders sensitive line rats: a genetic animal model of 
depression. Neuroscience & Biobehavioral Reviews 17, 51-68. 
 24 
Pandya, A.A., and Yakel, J.L. (2013). Effects of neuronal nicotinic acetylcholine 
receptor allosteric modulators in animal behavior studies. Biochemical pharmacology 86, 
1054-1062. 
Picciotto, M.R., Addy, N.A., Mineur, Y.S., and Brunzell, D.H. (2008). It is not "either/or": 
Activation and desensitization of nicotinic acetylcholine receptors both contribute to 
behaviors related to nicotine addiction and mood. Prog Neurobiol 84, 329-342. 
Pons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J.M., Changeux, J.P., 
Maskos, U., and Fratta, W. (2008). Crucial role of α4 and α6 nicotinic acetylcholine 
receptor subunits from ventral tegmental area in systemic nicotine self-administration. J 
Neurosci 28, 12318-12327. 
Prickaerts, J., van Goethem, N.P., Chesworth, R., Shapiro, G., Boess, F.G., Methfessel, C., 
Reneerkens, O.A., Flood, D.G., Hilt, D., and Gawryl, M. (2012). EVP-6124, a novel and 
selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance 
by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. 
Neuropharmacology 62, 1099-1110. 
Pucilowski, O., Overstreet, D.H., Rezvani, A.H., and Janowsky, D.S. (1993). Chronic mild 
stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiology & 
behavior 54, 1215-1220. 
Rabenstein, R., Caldarone, B., and Picciotto, M. (2006). The nicotinic antagonist 
mecamylamine has antidepressant-like effects in wild-type but not β2-or α7-nicotinic 
acetylcholine receptor subunit knockout mice. Psychopharmacology 189, 395-401. 
Roth, B.L., Sheffler, D.J., and Kroeze, W.K. (2004). Magic shotguns versus magic bullets: 
selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug 
Discov 3, 353-359. 
SalÃn-Pascual, R.J., Rosas, M., Jimenez-Genchi, A., and Rivera-Meza, B.L. (1996). 
Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major 
depression. Journal of Clinical Psychiatry. 
Seeman, P. (2002). Atypical antipsychotics: mechanism of action. Canadian journal of 
psychiatry Revue canadienne de psychiatrie 47, 27-38. 
Spande, T.F., Garraffo, H.M., Edwards, M.W., Yeh, H.J., Pannell, L., and Daly, J.W. 
(1992). Epibatidine: a novel (chloropyridyl) azabicycloheptane with potent analgesic 
activity from an Ecuadoran poison frog. Journal of the American Chemical Society 114, 
3475-3478. 
Steinlein, O.K., Mulley, J.C., Propping, P., Wallace, R.H., Phillips, H.A., Sutherland, G.R., 
Scheffer, I.E., and Berkovic, S.F. (1995). A missense mutation in the neuronal nicotinic 
acetylcholine receptor a4 subunit is associated with autosomal dominant nocturnal frontal 
lobe epilepsy. Nat Genet 11, 201-203. 
 25 
Swope, S.L., Qu, Z., and Huganir, R.L. (1995). Phosphorylation of the Nicotinic 
Acetylcholine Receptor by Protein Tyrosine Kinasesa. Annals of the New York Academy 
of Sciences 757, 197-214. 
Tang, J., and Dani, J.A. (2009). Dopamine enables in vivo synaptic plasticity associated 
with the addictive drug nicotine. Neuron 63, 673-682. 
Tanner, C.M., Goldman, S.M., Aston, D.A., Ottman, R., Ellenberg, J., Mayeux, R., and 
Langston, J.W. (2002). Smoking and Parkinson's disease in twins. Neurology 58, 581-588. 
Unwin, N. (2005). Refined Structure of the Nicotinic Acetylcholine Receptor at 4A 
Resolution. J Mol Biol 346, 967-989. 
Williams, D.K., Peng, C., Kimbrell, M.R., and Papke, R.L. (2012). Intrinsically low open 
probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric 
modulation and serum factors leading to the generation of excitotoxic currents at 
physiological temperatures. Molecular pharmacology 82, 746-759. 
Williams, D.K., Wang, J., and Papke, R.L. (2011). Positive allosteric modulators as an 
approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and 
limitations. Biochemical pharmacology 82, 915-930. 
Williams, J.M., Ziedonis, D.M., Abanyie, F., Steinberg, M.L., Foulds, J., and Benowitz, 
N.L. (2005). Increased nicotine and cotinine levels in smokers with schizophrenia and 
schizoaffective disorder is not a metabolic effect. Schizophrenia research 79, 323-335. 
Zwart, R., and Vijverberg, H.P. (1998). Four Pharmacologically Distinct Subtypes of α4β2 
Nicotinic Acetylcholine Receptor Expressed in Xenopus laevisOocytes. Molecular 
pharmacology 54, 1124-1131. 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
 
 
 
Chapter II: 
Lynx1 shifts α4β2 nicotinic receptor subunit stoichiometry by 
affecting assembly in the endoplasmic reticulum* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This chapter has been submitted as a manuscript to The Journal of Biological Chemistry 
by the authors Weston A. Nichols, Brandon J. Henderson, Caroline Yu, Rell L. Parker, 
Christopher I. Richards, Henry A. Lester, and Julie M. Miwa. 
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Abstract 
 
GPI-anchored neurotoxin-like receptor binding proteins, such as lynx modulators, are 
topologically positioned to exert pharmacological effects by binding to the extracellular 
portion of nAChRs. These actions are generally thought to proceed when both lynx and the 
nAChRs are on the plasma membrane. Here, we demonstrate that lynx1 also exerts effects 
on α4β2 nAChRs within the endoplasmic reticulum. Lynx affects assembly of nascent α4 
and β2 subunits, and alters the stoichiometry of the population that reaches the plasma 
membrane. Additionally, these data suggest that lynx1 alters nAChR stoichiometry 
primarily through this intracellular interaction, rather than via effects on plasma membrane 
nAChRs. To our knowledge, these data represent the first test of the hypothesis that a lynx 
family member, or indeed any GPI-anchored protein, could act within the cell to alter 
assembly of multi-subunit protein. 
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Introduction 
Cholinergic systems are involved in diverse functions including mood, anxiety, 
learning and memory, addiction, and movement disorders (Miwa et al., 2011). The 
nicotinic acetylcholine receptors (nAChRs) of the cholinergic system are comprised of 15 
different subunits (α1-10 and β1-4) which assemble into both homopentameric receptors 
such as (α7)5 or (α9)5 and heteropentameric receptors such as α4β2 (Jensen et al., 2005). 
Subunit composition, and even the position of specific subunits within pentamers, can 
influence the biophysical, pharmacological, and cell biological properties of the receptor, 
with profound effects on information processing in neurons that express these nAChRs 
(Gotti et al., 2009).  
Subunit composition influences the properties of the two possible pentameric 
stoichiometries of α4β2 nAChRs, the most abundant heteromeric nAChR subtype in the 
brain. In a terminology that emphasizes their differences with respect to acute 
pharmacology, the (α4)3(β2)2 receptors are known as low sensitivity (LS) receptors, while 
(α4)2(β2)3 receptors are known as high sensitivity or (HS) receptors (Moroni et al., 2006) 
(Gotti et al., 2009). These two stoichiometries exhibit different desensitization kinetics and 
respond differently to chronic nicotine treatment. HS receptors are upregulated in response 
to nicotine, while LS receptors are unaffected. This is thought to play an important role in 
mechanisms of nicotine addiction (Nelson et al., 2003; Srinivasan et al., 2014). 
Additionally, subunit composition could possibly influence sub-cellular localization of 
receptors on the plasma membrane (PM). 
The lynx family proteins are a subset of the Ly6/uPAR superfamily. This 
superfamily is related to the elapid snake venom toxin genes, such as α-bungarotoxin, 
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consisting of a three-fingered folding motif and multiple internal disulfide bonds 
(Lyukmanova et al., 2011; Miwa et al., 1999). α-bungarotoxin and other such toxins 
exemplify a highly conserved receptor binding motif which is also carried over to lynx 
proteins (Lyukmanova et al., 2011; Miwa et al., 1999; Miwa et al., 2012). α-bungarotoxin 
and other toxins have become widely used probes for the investigation of the properties of 
nAChR. Snakes inject these toxins into their prey; in contrast, the role of a toxin-like 
molecule expressed within a cell together with nAChRs has not been widely studied. Since 
the discovery of lynx1, many other lynx family members have been found, and several 
include GPI anchors (Chimienti et al., 2003; Miwa et al., 2011; Miwa et al., 2012). The 
GPI-linked lynx1 and lynx2 molecules are presumably present in membranes early in the 
exocytotic pathway, such as the endoplasmic reticulum (ER). Therefore, the existence of 
the GPI-anchor on lynx1 and lynx2 proteins could contribute to the structure, composition, 
or function of nascent nAChRs as well. 
The differential contributions of lynx genes to brain function are influenced to a 
large degree by the regions of expression. For instance, lynx1 is widely expressed 
throughout the brain, with high levels in the cerebral cortex and hippocampus, playing a 
role in learning and neuronal plasticity (Miwa et al., 2006; Miwa and Walz, 2012; 
Morishita et al., 2010). The lynx2 gene, in contrast, has a more restricted expression with 
high levels in the fear/anxiety structure of the amygdala, and lynx2 KO mice display 
elevated fear and anxiety-related behaviors (Tekinay et al., 2009). Selectivity for nAChR 
subtypes (α7 and β2 nAChRs) have also been found for lynx1 proteins, and could provide 
another level of regulation as yet not well explored. 
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GPI-anchored neurotoxin-like receptor binding proteins, such as lynx 
modulators, are confined to a volume just a few nanometers above the extracellular face of 
the membrane. This topology positions them to exert pharmacological effects by binding to 
the extracellular portion of nAChRs. These actions have previously been thought to 
proceed on the PM. Among the pharmacological effects of small-molecule ligands is 
pharmacological chaperoning of α4β2 nAChRs; this proceeds when the ligands enter the 
ER (Srinivasan et al., 2014) and, perhaps, the Golgi (Henderson et al., 2014). Thus far, 
there have been no reports of lynx modulators exerting an effect inside cells. Here, we 
investigated the hypothesis that lynx1 also exerts an effect on α4β2 nAChRs within the 
endoplasmic (ER) reticulum. To our knowledge, these data represent the first report of a 
lynx family member, or indeed any GPI-anchored protein, acting within the cell to alter 
assembly of multi-subunit proteins.  
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Experimental Procedures 
 
Plasmid Constructs 
 
Mouse lynx1 cDNAs including an N-terminally fused fluorescent tag (eGFP, 
mCherry, or SEP) were constructed by PCR amplification using the forward primer 5′-
gcctgcctgtggcccaggctatggtgagcaagggcgag-3′ and the reverse primer 5′- 
aggcacacacgtggcactccagcttgtacagctcgtccatgcc-3′, which overlap with both sequences before 
and after the N-terminal signal sequence of the lynx1-coding sequence (Figure 2-1A). Four 
XFP-lynx1 constructs were made with four different linkers separating the fluorescent tag 
from mature lynx1: 1. no linker, 2. Gly-Ser, 3. Gly-Gly-Ser-Gly, or 4. Tyr-Ser-Asp-Leu 
(YSDL). All experiments presented in this paper utilize the YSDL linker version of the 
construct because it has been used previously with another GPI-linked fusion protein, GFP-
CD59 (Kenworthy, 2004; Nichols et al., 2001, and Prasanna Satpute and Jennifer 
Lippincott-Schwartz, personal communication), and it was the first construct we validated 
via electrophysiology. This PCR product was then cloned directly into the vector 
containing the lynx1 gene using Pfu-Turbo polymerase.  
We used mouse α4-wt, α4-GFP, α4-mCherry, β2-wt, β2-GFP, and β2-mCherry 
cDNA clones inserted into pCI-NEO vectors as described previously (Nashmi et al., 2003).   
 
Tissue Culture and Transfection 
Mouse neuroblastoma-2a (N2a) cells were cultured using standard techniques and 
maintained in DMEM (Invitrogen) supplemented with 10% FBS. N2a cells were plated by 
adding 90,000 cells to poly-d-lysine-coated 35-mm glass-bottom imaging dishes (MatTek, 
Ashland, MA). The next day, plasmid DNA was mixed with cationic lipids by adding 500-
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750 ng of each nAChR plasmid and lynx1 construct to 4 µl of Lipofectamine 2000 
transfection reagent in 200 µl of OptiMEM (Invitrogen). After 20 min at room temperature, 
the transfection mixture was added to N2a cells in 1 ml of plating medium and incubated at 
37 °C for 24 h. Dishes were rinsed twice with plating medium and incubated at 37 °C for 
an additional 24 h before imaging or electrophysiological experiments. HEK293 cells were 
also cultured using standard cell techniques as detailed above. N2A cells and HEK293 cells 
were obtained from ATCC (Manassas, VA). 
Primary mouse E16.5 neurons were extracted from mouse embryos and plated on 
35-mm polylysine-coated glass bottom culture dishes (Mattek) in a neuronal medium 
containing Neurobasal, B27 (Invitrogen), and Glutamax supplemented with 3% equine 
serum. We defined this initial plating as day-in-vitro zero (div 0). Neurons were plated at a 
density of 60,000 cells per dish. On div 4, neurons were treated with 1 µM cytosine 
arabinoside to halt the division of glial cells. Neurons were maintained via 50% exchange 
with feeding medium (Neurobasal, B27, and Glutamax) twice per week. On div 9, plasmids 
were mixed in 100 µl of OptiMEM, and 4 µl of Lipofectamine-2000 was mixed with a 
separate 100-µl aliquot of OptiMEM. After 5 min at room temperature, the separate 
solutions were mixed together and kept at room temperature for an additional 25 min. 
Neurons were transfected with 750 ng of each nAChR plasmid and of XFP-lynx1 plasmid. 
After 3 h at 37 °C, transfection medium was replaced with neuronal feeding medium. 
Neurons were imaged on day in vitro (div) 10.  
 
Co-immunoprecipitation 
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HEK293 cells were plated (on day 1) at a density of 4 million cells per 10 cm 
dish. Cells were transfected on day 2 with 5 µg of each construct DNA using ExpressFect 
reagent (Denville Scientific, South Plainfield, NJ) according to the manufacturer’s 
protocol. On day 3, medium was aspirated gently and replaced with fresh growth medium. 
Cells were harvested on day 4 by removing cells from 37 °C incubator, placing on ice, 
scraping cells from dish with a cell scraper (Corning Inc., Corning, NY), and transferring 
cells to a 15 mL conical tube for centrifugation and lysis. Cells were lysed in 1 mL of ice-
cold NP40 extraction buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 1% NP40, 1 mM EDTA, 
1 mM EGTA, 1% P8340 and 4 mM phenylmethylsulfonyl fluoride (PMSF)) by gently 
pipetting up and down 25 times. Cell lysate was centrifuged for 5 min at 4 °C and then 
combined with preformed complexes of protein A Dynabeads (Invitrogen, Carlsbad, CA) 
and rabbit-anti-GFP antibody (A11122, Molecular Probes, Invitrogen) for 
immunoprecipitation at room temperature on a rocker for 1 h. Dynabead-antibody-antigen 
complexes were removed from the supernatant via magnet, and washed. Complexes were 
dissociated by incubating in reducing buffer (50% Laemmli sample buffer, BIO-RAD, 
Hercules, CA) for 10 min at 70 °C. Dissociated samples were removed from beads via 
magnet, allowed to cool on ice, and loaded into an SDS-PAGE gel for Western blot 
analysis. 
 
Western Blot 
Samples were run on an SDS-PAGE protein gel, transferred to a nitrocellulose 
membrane, blocked with blocking buffer (TBS with 0.1% Tween-20 + 5% dry milk), and 
probed with goat-anti-lynx primary antibody (sc-23060, Santa Cruz Biotechnology, Santa 
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Cruz, CA). Of three antibody lots purchased from the supplier, only one gave 
satisfactory results; unfortunately that lot is no longer available. Membranes were probed 
with secondary IR800-anti-goat antibody (926-32214, Li-Cor Biosciences, Lincoln, NE). 
Membranes were then imaged in an Odyssey near infrared imager (Li-Cor Biosciences). 
 
Confocal Microscopy 
N2a cells and neurons were imaged as described previously (Drenan et al., 2008; 
Moss et al., 2009) in L15 Buffer (150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 
10 mM HEPES, and 10 mM D-glucose, pH 7.4), a CO2 independent media. Briefly, cells 
were imaged with a Nikon (Nikon Instruments, Melville, NY) C1 laser-scanning confocal 
microscope system equipped with spectral imaging capabilities and a Prior (Rockland, ME) 
remote-focus device, and a Nikon Plan Apo 60X 1.40 NA oil objective. Pinhole diameter 
was 30-60 µm, and cells were imaged at 12-bit intensity resolution over 512 × 512 pixels at 
a pixel dwell time 6.72 µs. GFP was excited using a 488 nm modulated diode laser, and 
mCherry was excited with an argon laser at 561 nm. In most cases, imaging was carried out 
using the Nikon C1si DEES grating and spectral detector with 32 parallel photomultiplier 
tubes. This allowed us to collect spectral images (λ stacks). In such images, each pixel of 
the X-Y image contains a list of emission intensity values across a range of wavelengths. 
We collected light at wavelength intervals between 485 and 650 nm, at steps of 5 nm. We 
used the Nikon EZC1 linear unmixing algorithm to reconstruct GFP and mCherry images. 
For each pixel of a spectral image, intensity of GFP and mCherry was determined from 
fluorescence intensity values at the peak emission wavelength derived from the reference 
spectra.  
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Phosphotidylinositol-specific phospholipase C (PI-PLC) (CAS #: 37288-19-0, 
Product #: P8804, Sigma-Aldrich) was used to cleave the GPI-anchor of lynx1, and thus 
cleave the protein from the PM. After addition of 0.25 units/mL of PI-PLC to cell culture 
dish, cells were incubated for 1 h at 37 °C either in a mammalian cell incubator or within a 
climate-controlled chamber on the microscope stage (for before and after images). After PI-
PLC treatment, cells were briefly washed twice with 2 ml of fresh medium and 
subsequently imaged. An aqueous glycerol solution buffer of 60% v/v glycerol, 10 mM 
Tris HCl, 10 mM EDTA, at a pH of 8.0 was used as a control with no PI-PLC enzyme. 
 
Measuring FRET with Donor Recovery After Photobleaching (DRAP) 
To examine FRET between various nAChR subunits, the acceptor photobleaching 
method was used with a modified fluorescence recovery after photobleaching macro built 
into the Nikon EZC1 imaging software, as described previously (Drenan et al.). In this 
method, FRET was detected by recording GFP signal increases during incremental 
photodestruction of mCherry. A spectral image was acquired once before mCherry 
bleaching and at six time points during mCherry bleaching at 561 nm. Laser power during 
bleaching was constant at 80%. One bleach scan per cycle was used. This bleaching 
protocol was optimized to achieve 75 to 90% photodestruction of mCherry while still 
enabling us to record incremental increases in GFP emission at each time point. To 
measure FRET, spectral images were unmixed into their GFP and mCherry components as 
described above. We measured GFP and mCherry mean intensity throughout the entire cell 
by selecting the cell perimeter as the boundary of a region of interest in Nikon's EZC1 
software. GFP and mCherry components were saved in Excel format, and fluorescence 
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intensities were normalized to the pre-bleach time point (100%). FRET efficiency (E) 
was calculated as E = 1 - (IDA/ID), where IDA represents the normalized fluorescence 
intensity of GFP (100%) in the presence of both donor (GFP) and acceptor (mCherry), 
and ID represents the normalized fluorescence intensity of GFP in the presence of donor 
only (complete photo-destruction of mCherry). The ID value was extrapolated from a 
scatter plot of the fractional increase of CFP versus the fractional decrease of YFP. 
The E values were averaged from several cells per condition. 
 
Mammalian Cell Electrophysiology 
N2a cells were co-transfected with nAChR subunits tagged with eGFP to facilitate 
visual identification of transfected cells.  We used an inverted fluorescence microscope 
(IX71, Olympus) equipped with an Hg lamp (HB-10103AF, Nikon) to visualize the 
fluorescent cells. Whole-cell voltage-clamp currents were recorded using an Axopatch-1D 
amplifier (Axon Instruments) and digitized with a Digidata 1440A analog-to-digital 
converter (Axon) under the control of pClamp 10.0 software (Axon). The pipette solution 
contained (in mM): 135 K gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2 Mg-ATP, 
and 0.1 GTP, pH adjusted to 7.2 with Tris-base, osmolarity to 280-300 mOsm with 
sucrose).  Electrode resistance was 2-6 MΩ. All recordings were obtained at ambient 
temperature.  Data were low-passed filtered at 2 kHz and sampled at 10 kHz. ACh was 
dissolved in an extracellular solution containing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES, and 10 glucose (320 mOsm, pH to 7.3 with Tris-base), and applied to 
cells using a Picospritzer (20 psi) or a commercially available microperfusion system 
(Octaflow II, ALA Scientific Instruments). The holding potential was -50 mV.  To 
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minimize agonist-induced desensitization, we applied ACh at ~3 min intervals, and 
continually perfused the recording chamber with extracellular solution.   
Phosphotidylinositol-specific phospholipase C (PI-PLC) was used to cleave lynx1 
from the PM. We exposed cells to 0.25 units/mL for 1 h at 37 °C incubation prior to 
electrophysiology assays. 
 
Statistical Analysis 
Concentration-response relations for the ACh-induced fluorescent membrane 
potential changes and voltage-clamp currents were fit to the Hill equation using nonlinear 
least-squares regression (OriginLab software).  Errors reported for the mean values are ± 
SEM. Statistical significance was determined by either Student’s t test or by one-way 
analysis of variance (ANOVA) where multiple pairwise comparisons were conducted.  
Significant differences are reported at the level of p<0.05 (*), p<0.01 (**), or p<0.001 
(***). 
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Results 
Construction of XFP-lynx1 reveals subcellular localization both on the plasma 
membrane and in the endoplasmic reticulum.  
We constructed four variants of the mCherry-lynx1 construct, each with a unique 
linker as described in Methods. The mCherry was inserted after the N-terminal signal 
sequence and before the mature lynx1 protein sequence as shown in Figure 2-1A. All four 
variants are fluorescent, indicating that the mCherry fluorophore folds properly. We 
proceeded with electrophysiological validation of the construct with the YSDL linker (see 
Figures 2-3 and 2-5 below) because that particular linker had been previously characterized 
on a similar fluorescent GPI-linked fusion protein, GFP-CD59 (Nichols et al., 2001), After 
validation by electrophysiology, we made two additional constructs by replacing the 
mCherry sequence with that of GFP or superecliptic pHluorin (SEP). To test the similarity 
of the GFP and mCherry constructs, we co-transfected them together into cultured mouse 
E16.5 cortical neurons (Figure 2-1B). Both constructs show a patchy, segmented 
appearance. We compared this distribution to that of two other proteins. We co-transfected 
GFP-lynx1 with tau1-mCherry (Figure 2-1D). The tau1-mCherry localizes to microtubules, 
allowing visualization of processes to determine whether they are segments. We found that 
most of the neurons in the dish had less patchy tau1-mCherry fluorescence than GFP-lynx1 
fluorescence, suggesting that lynx1 may normally be present in clusters within cells.  This 
may be due to the GPI–anchor interacting with specific cholesterol-rich membrane 
domains. When co-transfected with GalT-mCherry, GFP-lynx1 showed little overlap 
(Figure 2-1E), indicating that most lynx1 molecules did not reside in the trans-Golgi 
network.  
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Figure 2-2. Lynx1 is present in ER in addition to the PM. A. Construction of fluorescently-
tagged lynx1 constructs, schematic of GFP, mCherry or SEP insertion after the N-terminal 
signal sequence of lynx1. B-E, mouse E16.5 neurons transfected with various fluorescently-
tagged proteins. B, both GFP-lynx1 and mCherry-lynx1. C, GFP-lynx1 and tau1-mCherry, a 
marker for microtubules, partially colocalize. D, GFP-lynx1 and GalT-mCherry, indicating that 
the majority of lynx1 is outside the Golgi. E, SEP-lynx1 and ER-dsRED, at both pH 7.4 and 
5.5. Quenching at pH 5.5 indicates that lynx1 is present both in the ER and on the plasma 
membrane. F, Topology of an α4- or β2-GFP construct. α4- or β2-GFP nAChRs were labeled 
with a genetically encoded GFP inserted into the intracellular M3-M4 loop. The cartoon of 
nAChR derives from PDB 2BG9, and the cytoplasmic portions are incomplete. G, Co-
immunoprecipitation indicates that lynx1 binds and forms stable complexes with α4-GFP both 
with β2 present (lane 1) and with no other nAChR subunits present (lane 2). α4 subunits alone 
are unable to leave the ER, thus lynx1 must bind in the ER. lynx1 was not detectable when 
either co-transfected with β2-GFP (lane 3), or alone (lane 4). 
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SEP is a pH-sensitive version of GFP with a pKa of ~ 7.0. SEP is fluorescent at 
pH 7.4, but is quenched at pH < 7.0 (Miesenböck et al., 1998). SEP provides information 
about the percentage of receptors that are present on the PM when linked to the 
extracellular portion of Cys-loop receptors (Henderson et al., 2014; Jacob et al., 2005; 
Khiroug et al., 2009; Richards et al., 2011) and other membrane proteins. We used this pH 
dependence to visualize and discriminate between SEP-lynx1 molecules residing 
intracellularly vs. those residing on the PM, as shown in Figure 2-1E. When the pH was 
adjusted to 5.4 by perfusion, we observed that fluorescence decreased but did not 
disappear, suggesting that a population of SEP-lynx1 resides on the PM and a portion 
resides in the ER.  
 
Lynx1 binds α4-GFP in the ER 
Previous assays on HEK293T cells transfected with α4, β2 (both FLAG-tagged 
constructs), and lynx1, immunoprecipitation of either α4 with anti-α4 antibody (mAb299), 
or immunoprecipitation of both α4 and β2 with anti-FLAG antibodies, showed co-
immunoprecipitation of nAChRs with lynx1 (Ibanez-Tallon et al., 2002). Here, we 
demonstrate that lynx1 and α4 also co-immunoprecipitate when the β2 subunit is omitted 
(Figure 2-1F). Because α4 subunits alone do not form a complete, pentameric receptor, 
they do not efficiently leave the ER (Whiteaker et al., 1998).  
To test whether lynx1 could bind the individual subunits of the α4β2 nAChR and 
potentially affect assembly we co-transfected either: (1) α4-GFP, β2-wt, and lynx1; (2) α4-
GFP and lynx1; (3). β2-GFP and lynx1; or (4) lynx1 alone into HEK293 cells (Figure 2-1F, 
G). We probed for lynx1 after precipitating the nAChR subunits with an anti-GFP 
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antibody.  We found that when α4 is present, either alone or with β2, lynx1 was pulled 
down.  We could not detect lynx1 when β2-GFP precipitated down, or in the control where 
there was no nAChR subunit co-transfected (Figure 2-1G). Since it appears that lynx1 can 
bind the α4 subunit without the presence of β2, we conclude that lynx1 is able to bind to α4 
before pentamers are formed, suggesting that association of lynx1 with α4 occurs in the 
ER.  
 
lynx1 stabilizes α4/α4 dimers, but not β2/β2 dimers, in the ER 
To measure whether the presence of lynx1 affects receptor formation we conducted 
four types of donor-recovery after photo-bleaching (DRAP) FRET experiments on mouse 
N2a cells transfected with nAChR subunits plus or minus lynx1 (Figure 2-2). We co-
transfected α4-GFP, α4-mCherry, and either empty vector or lynx1(we did not co-transfect 
a β subunit). In this case, we measure DRAP between α4/α4 dimers in the ER, as α4 
without a β subunit cannot assemble into a full pentamer and subsequently cannot 
efficiently exit the ER. The addition of lynx1 increased the FRET efficiency between these 
dimers from (6.7% ± 1.13%, 26 cells) to (14.59% ± 1.51%, 32 cells), suggesting that lynx1 
binds α4 subunits in the ER, increasing dimerization and potentially assisting the formation 
of the LS stoichiometry (Figure 2-2A , B, and, E). In another series, we obtained FRET 
measurements between α4-GFP and α4-mCherry in the presence of β2-wt of (9.33% ± 
0.85%, 40 cells) and (3.09% ± 1.11%, 36 cells) with empty vector and lynx, respectively. 
When we co-expressed fluorescently labeled β2 subunits, β2-GFP and β2-mCherry, either 
in the presence or absence of α4-wt, the addition of lynx1 did not significantly alter the 
FRET efficiency (Figure 2-2 B1-B2, C1-C2, E). For β2-GFP/β2-mCherry with no α4-wt or 
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lynx, the FRET efficiency was (25.1% ± 2.79%, 31 cells); when lynx was added, the 
FRET efficiency was 27.5% ± 2.4%, (24 cells). For β2-GFP/β2-mCherry with α4-wt, the 
FRET efficiencies were (18.4% ± 1.3%, 29 cells), and (18.5% ± 1.7%, 33 cells) for empty 
vector and lynx, respectively. Data are reported here as (mean ± S.E.M., number of cells 
per condition).  
These data show that lynx1 increases the assembly of α4/α4 dimers and does not 
alter β2/β2 dimer assembly. To assess the effect of lynx1 on fully assembled α4β2 nAChR 
pentamers, we co-expressed α4-GFP, α4-mCherry, β2-wt, and either empty vector 
(pcDNA3.1) or lynx1. The addition of lynx1 increased the FRET between the fluorescently 
labeled α4 subunits, indicating that lynx1 increases the extent to which α4 subunits 
assemble together in complexes (Figure 2-2E). This shift could be due to increased 
incorporation of the α4 subunit into the auxiliary position of α4β2 fully formed pentamers 
(LS, (α4)3(β2)2 stoichiometry). It could also be due to increased α4/α4 dimers in the ER. 
These two outcomes are not mutually exclusive, in fact, the latter (increased α4/α4 dimers 
in the ER) would likely lead to the former by biasing assembly towards the formation of 
(α4)3(β2)2 (LS) nAChRs.  This would presumably result in more LS receptors being 
exported from the ER and eventually trafficked to the PM.  
A high baseline level of acceptor or low post-acceptor-bleaching level of donor 
could distort the measurements of FRET efficiency. To rule this out we calculated the ratio 
between GFP and mCherry expression (Figure 2-2F, G). We achieved ratios consistently 
between 0.6 to 2.0, which are within the acceptable range for DRAP measurements.  
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Figure 2-3. Donor recovery after photobleaching (DRAP). N2a cells were transfected with 
either α4-GFP and α4-mCherry (A1, A2, B1, and B2 show exemplar data) or β2-GFP and β2-
mCherry (C1, C2, D1, and D2 show exemplar data). The acceptor fluorophore (mCherry) was 
photobleached, causing an increase in fluorescence of the donor fluorophore (GFP). α4-GFP 
and α4-mCherry were co-transfected either with empty vector or with lynx1. β2-GFP and β2-
mCherry were co-transfected either with empty vector (C1-C2), or with lynx1 (D1-D2). Lynx1 
increases FRET efficiency between α4 subunits, but not between β2 subunits. E, lynx1 
increases FRET efficiency between α4-GFP and α4-mCherry subunits when no other subunits 
are present (top left) and also when co-transfected with β2 (bottom left). lynx1 does not 
increase FRET efficiency between fluorescently tagged β2 subunits either without α4 present 
(top right) or with co-transfected α4 (bottom right). F-G, lynx1 has no effect on the ratio of 
signals, GFP/mCherry for fluorescently tagged α4 (F) or β2 (G). Numbers within parentheses 
in bar graphs represent number of cells per condition.  
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lynx1 causes a shift in population stoichiometry of the α4β2 nAChR on the plasma membrane 
Previous studies on lynx1 showed that lynx1 reduces the sensitivity of α4β2 receptors to 
ACh, both in heterologous expression systems and in vivo (Ibanez-Tallon et al., 2002; Miwa et al., 
1999; Miwa et al., 2006). However, it has not been previously demonstrated that lynx1 shifts the 
stoichiometry of α4β2 receptors on the PM by biasing assembly of nascent subunits within the ER. 
To test this hypothesis, we completed a series of electrophysiology assays (Figure 2-3).These 
electrophysiological experiments examined the effect of lynx1 and fluorescently tagged XFP-lynx1 
on α4β2. We transfected N2a cells with α4-GFP and β2-wt nAChR subunits and either lynx1 (wt 
or mCherry) or empty vector. The addition of lynx1-wt or mCherry-lynx1 reduced peak current 
sizes, reduced the proportion of HS receptors, and decreased the decay time (Figure 2-3, Table 1). 
Addition of lynx1-wt reduced α4β2 nAChR peak current amplitude to ~40% of the maximal 
response, (from 3280 ± 1320 pA [5 cells] to 1,060, ± 402 pA, [6 cells]) for lynx1-wt (Figure 2-3A, 
B, D). Addition of mCherry-lynx1 similarly reduced the α4β2 nAChR peak current amplitude to 
~30% of the maximal response (539.4 ± 115 pA, 10 cells) (Figure 2-3A, C, D). There was no 
significant difference between lynx1-wt and mCherry-lynx1 in regards to mean peak current 
amplitude, decay time, or waveform (Figure 2-3D, E). This suggests that the addition of the 
mCherry fluorophore to lynx1 does not significantly alter its function. 
Next we collected concentration-response data to assess changes in α4β2 nAChR 
stoichiometry. Previous assays have validated that the LS and HS α4β2 nAChR stoichiometries 
have distinct pharmacological profiles: LS nAChRs and HS nAChRs have different EC50 values 
with ACh (~ 30µM and 3 µM, respectively) (Nelson et al., 2003; Tapia et al., 2007). Without 
lynx1, α4β2 nAChRs have a two-component dose-response relation, with a pronounced HS-like 
behavior at [ACh] ≤ 1 µM (Figure 2-3F). The addition of lynx1 (wt, or mCherry) produced less 
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pronounced responses at lower [ACh] (Figure 2-3F,). This suggests that in the presence of lynx1, 
the HS α4β2 nAChR population is decreased. Therefore, PM α4β2 nAChRs are composed mainly 
of LS α4β2 nAChRs. The Hill equation fits (Table 2-1) are consistent with a shift in components. 
In the absence of lynx1, ~50% of HS component (as often observed in α4β2 experiments); but in 
each of the lynx1 conditions this is reduced to ~25-28% HS. A compelling contrast is shown for 
the normalized data at 10 µM ACh (Figure 2-3G), which was chosen because this dose produces 
near maximal responses at HS receptors, with minimal contribution by LS receptor (Moroni et al., 
2006; Nelson et al., 2003).  
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Figure 2-4. Electrophysiology in Neuroblastoma-2a cells: lynx1-wt and mCherry-lynx1 have 
similar effects on α4β2. A-C, sample traces from N2a cells transfected with α4-GFP, β2-wt, 
and either empty vector (A), lynx1-wt (B), or mCherry-lynx1 (C) where ACh was puffed for 
100 ms. D, Both lynx1-wt and mCherry-lynx1 decrease peak currents at 300 µM ACh when 
compared to empty vector. E, traces from N2a cells when transfected with α4β2 and either 
lynx1-wt or mCherry-lynx1. F-G. Addition of lynx1 variants shifts the dose-response relation 
of α4β2 to the right, towards a greater proportion of the low-sensitivity (α4)3(β2)2 
stoichiometry. F, Dose-response curves of α4β2 when co-transfected with empty vector, 
lynx1, mCherry-lynx1, or lynx1 and treatment with phospholipase-C (PLC) for 1 h at 37 °C. 
G, Comparison of normalized current between α4β2 and lynx1 variant conditions at 10 µM 
ACh. 10 µM was selected to maximize activation of high-sensitivity (EC50 ≈ 3 µM) 
stoichiometry (α4)2(β2)3 receptors, while minimizing activation of the lower-sensitivity (EC50 
≈ 50 µM) stoichiometry (α4)3(β2)2 receptors. The maximal response is significantly reduced 
for the three lynx1 variants. There is no significant difference between lynx1, mCherry-lynx, 
and lynx1 plus PLC treatment. Numbers within parentheses in bar graphs represent number 
of cells per condition.  
 
 
 
 
  
Table 1. Comparison of two-component fits to α4β2 dose-response relations in N2a cells 
when co-transfected with empty vector, or one of three lynx1 conditions 
α4β2 ACh HS EC50 Err HS n Err LS EC50 Err LS n Err %HS R2 
wt +pcDNA 2.34 1.38 0.86 0.43 36.9 20.1 1.5 0.76 50.3% 0.97 
+lynx-pTracer 5.42 3.36 1.5 1.18 61.4 14.1 1.5 0.44 27.0% 0.99 
+ mC-lynx 2.49 1.41 1.05 0.76 58.6 12.8 1.5 0.37 28.4% 0.99 
Lynx+PLC  6.55 9.47 0.54 0.41 41.9 14.7 1.5 0.37 24.9% 0.99 
Table 1. Fitted parameters for ACh concentration-response relations of α4β2 when co-
transfected with empty vector, lynx1-wt, mCherry-lynx1, and lynx1-wt after treatment with PI-
PLC. Parameters correspond to ACh concentration-response relations in Figure 2-3. The EC50 
and Hill coefficient values represent the mean ± SEM for the number of measurements (n) 
obtained. The relative fraction of the high sensitivity component (1st comp) for the biphasic 
relations is included.lynx1, mCherry-lynx1, or lynx1 plus PLC treatment. Fits were generated 
under two assumptions: 1. All HS receptors, and no LS receptors, are activated at 10 µM ACh; 
2. Hill coefficients were constrained to <= 1.5.  
 
PI-PLC treatment cleaves lynx1 from the plasma membrane 
We cleaved the GPI anchor of lynx1, releasing lynx1 from the PM via treatment 
with phosphatidylinositol-specific phospholipase C (PI-PLC). This allowed us to determine 
whether acute removal of surface lynx1 affects the response of α4β2 nAChRs. Using 
confocal imaging, we demonstrate that we can remove lynx1 from the PM of N2a cells 
expressing α4β2 nAChRs and mCherry-lynx1 (Figure 2-4). Before treatment with PI-PLC, 
“railroad tracks” of red fluorescence are clear on the borders of processes, indicating 
mCherry-lynx1 on the PM, and these are quantified by intensities in typical line profiles 
where the peaks align with the borders. After PI-PLC treatment for 1 h the membrane 
fluorescence is decreased and becomes undetectable above background (Figure 2-4A, B). 
This can be seen clearly through line profiles (Figure 2-4C, D). In control experiments, 
  
 
Figure 2-5. PI-PLC treatment cleaves mCherry-lynx1 from the plasma membrane. A, 
images of N2a cells transfected with α4-GFP, β2-wt, and mCherry-lynx1 taken with a 
confocal microscope before and after treatment with phosphatidylinositol-specific 
phospholipase C (PI-PLC). B-C, line profiles quantifying fluorescence levels across a line 
demonstrate the presence of the ‘railroad track’ morphology of mCherry-lynx1 on the 
membrane of N2a cells before treatment with PLC (B), and after (C). The arrows point to 
the lines used for quantification. 100 pixels = 10 µm. These data are typical of 5 
experiments. 
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Figure 2-5. PLC treatment does not affect ACh-induced currents of cells transfected with α4β2 
and lynx1. A-C, example traces  from N2a cells transfected with α4, β2, and either (A) empty 
vector, (B) lynx1, or (C) lynx1 with subsequent PLC treatment. Cells were subjected to 100 µM 
ACh for 10 s to measure both peak current and desensitization (quantified here as the time 
between 90% and 10% of max current). D, Overlay of traces comparing lynx1 with or without 
PLC treatment. PLC does not alter peak current (E) or decay time (F) of N2a cells transfected with 
α4, β2, and lynx1. However, lynx1 does shorten the decay time compared to α4β2 alone both 
without and with PLC treatment. Panel F presents a shift in 90% to 10% decay time from 6.14 ± 
0.55 sec for empty vector to 2.35 ± 0.37 sec and 2.68 ± 0.46 sec for lynx-wt and lynx1-wt + PLC, 
respectively 
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cells were treated with identical solution lacking PI-PLC and we observed no reduction 
in PM “railroad-track” appearance or line profile quantification (Figure 2-6). 
 
PI-PLC treatment does not affect dose response-relations to ACh, peak current, or signal 
decay time of α4β2 + lynx1.  
Before and after treatment with PI-PLC to cleave lynx1, we performed 
electrophysiological experiments to measure concentration-response relations to ACh 
(Figure 2-3F). After PI-PLC treatment, the peak currents and concentration response curve 
were not different when compared to lynx1-wt and mCherry-lynx1 conditions (Figure 2-
3F). Peak current amplitude at saturating concentrations of ACh (300 µM) and 
desensitization kinetics (90% to 10% of maximal current) were not different when 
comparing lynx1-wt plus PLC and lynx1-wt without PI-PLC (Figure 2-5). We confirmed 
earlier observations that the presence of lynx does accelerate desensitization of α4β2 
currents (Ibanez-Tallon et al., 2002; Miwa et al., 2006). However, this acceleration is not 
reversed by PI-PLC treatment. Overlay of α4β2 nAChRs with lynx1 (treated or not treated 
with PI-PLC) show a close overlap and little difference among waveforms (Figure 2-5D). 
These results suggest that the major effects of lynx1 on α4β2 occur before the nAChRs 
appear on the PM. The data together suggest that lynx1 exerts its effects intracellularly, 
stabilizing α4/α4 dimers in the ER, thus favoring the LS (α4)3(β2)2 stoichiometry.  
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Figure 2-6. Control treatment does not affect the ‘railroad track’ fluorescence signal of mCherry-
lynx1. A, images of N2a cells transfected with α4-GFP, β2, and mCherry-lynx1 before and after 
treatment with control glycerol-containing solution but without PLC. B-C, line profile 
quantifications visualize the persistence of the ‘train-track’ twin peaks as cells remain in an 
environment-controlled chamber on the confocal microscope. 
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Discussion 
Our data lead to three conclusions. First, we demonstrate that lynx1 binds α4 
nAChR subunits in the ER and increases α4/α4 dimer formation. Second, lynx1 biases the 
stoichiometry of α4β2 receptors toward LS assembly of α4β2 nAChRs. Finally, the 
minimal effects of removing lynx1 at the PM suggest that lynx1 exerts its effects on 
nascent receptors within the ER, thereby influencing receptor assembly and the 
stoichiometry of the final receptor exported to the PM. To our knowledge, this is the first 
report of a GPI-anchored protein playing a role in regulating assembly of a multimeric 
protein through an intracellular mechanism.  
It has been previously demonstrated that the expression of lynx1 shifts α4β2 to the 
LS stoichiometry, and the removal of lynx1 increases sensitivity (Ibanez-Tallon et al., 
2002; Miwa et al., 2006). The molecular mechanisms for these actions, however, had yet to 
be addressed. Taking into account the relationship between lynx genes and snake venom 
toxins, a straightforward mechanism of lynx binding to the extracellular portion of the 
receptor on the cell surface to influence gating, has been the assumed mode of action for 
lynx proteins (Lyukmanova et al., 2011; Miwa et al., 1999). In this study, we applied new 
tools to demonstrate that lynx1 is resident both on the cell surface and in the interior of the 
cell. Apparently, the internal lynx1/α4 interactions are dominant, because removing surface 
lynx had little effect on receptor function. The most likely mechanism is that lynx1 controls 
the functional properties of nAChRs by influencing the type and number of receptors 
during receptor assembly.  
If lynx1 does exert a functional gating effect on PM α4β2 nAChRs, it may be 
effective after cleavage of the GPI anchor and/or at very high concentrations. Indeed, 
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exogenously applied lynx1 (minus the GPI anchor) alters the peak response of α4β2 
nAChRs to nicotine and ACh in vitro (Miwa et al., 1999). Further, previous studies in vivo 
show that overexpression of secreted lynx1 in mouse cerebellum, a region involved in 
motor learning, results in enhanced motor learning (Miwa and Walz, 2012), a behavioral 
phenotype similar to the lynx1-KO mice. Our results cannot definitively exclude a 
mechanism by which the lynx1 proteins that were previously bound to receptors prior to 
PI-PLC treatment remained bound after GPI-anchor cleavage. In this scenario, these 
interactions may have continued to influence gating function, but the concentration of 
bound lynx molecules were below the detection threshold of our confocal imaging assay. A 
mechanism in which the normal function of lynx1 is to act in trans at the post-synaptic 
membrane was not addressed and awaits further studies. 
Single channel studies of α4β2 and lynx1 in CHO cells indicate a shift in the 
proportion of channel openings toward higher amplitude, faster inactivating species 
(Ibanez-Tallon et al., 2002). The two different amplitudes of single channel openings may 
arise from the two different stoichiometries, where the (α4)3(β2)2 stoichiometry mediates 
larger amplitude opening (Tapia et al., 2007). The interactions of lynx1 and α4/ α4 subunits 
are likely to shift the internal concentration of total α4/α4 interfaces, and since an α4/α4 
interface occurs only in the (α4)3(β2)2 nAChR stoichiometry, then this could explain the 
greater expression of (α4)3(β2)2 nAChRs when lynx1 is present. Since (α4)3(β2)2 nAChRs 
are also thought to inactivate more rapidly. The accelerated decay of the macroscopic 
current in cells co-transfected with lynx1 might be explained by this stoichiometry shift. A 
lynx1 based model of pentameric receptor assembly might be slightly different than those 
previously put forth. It is generally thought that α4/β2 dimers are formed first, and the fifth 
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position is filled by either an α4 or β2 subunit. The lynx1-nAChR interaction might 
affect this final step, in favor of incorporating α4 subunits. Increasing the α4/α4 population 
may influence the expression of fully formed receptors, resulting in both greater selectivity 
(shift in stoichiometry), and less efficiency (reduction in the total number of receptors).  
The preferential affinity of lynx1 for α/α interfaces invites parallels with the ability 
of α-Btx to bind to α7 nAChRs. We might predict that the effect of lynx1 on monomeric 
nAChRs would differ from effects on those that can express multiple stoichiometries. It is 
interesting to note that nicotine binds to α/β interfaces, and prolonged nicotine binding 
within the ER is thought to upregulate α4β2 nAChRs by stabilizing the (α4)2(β2)3 
stoichiometry (Henderson et al., 2014; Lester et al., 2009; Nashmi et al., 2007; Srinivasan 
et al., 2011). Our data suggest that lynx1 could oppose some of the effects of chronic 
nicotine, by shifting the dimer concentration towards the α4/α4 species (Ibanez-Tallon et 
al., 2002). The differential up-regulation by chronic nicotine exposure in the brain may be 
due in part to the differential expression of lynx1 genes in different neuronal cell types. 
Our data are consistent with the possibility that interactions between α4 nAChR 
subunits and lynx1 could be a long-term interaction initiated in the ER, and sustained 
throughout the lifetime of the receptor. This presents the possibility of a multi-modal action 
of lynx1 on several aspects of cholinergic signaling. This should be taken into account 
when one considers models of lynx1 action on the function of the cholinergic system in the 
brain. The control that lynx1 exerts on cholinergic tone through nAChR interactions (Miwa 
et al., 2011; Miwa et al., 2012; Morishita et al., 2010), makes lynx1 a reasonable target for 
pharmaceutical drug development. There are several drug candidates targeting nAChRs in 
development (Gault et al., 2013; Hauser et al., 2009; Lieberman et al., 2013; Prickaerts et 
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al., 2012), and some may act by potentiating nAChRs (Harvey et al., 2014; Kanner, 
2013; Prickaerts et al., 2012; Putman and Dasse, 2013; Timmermann et al., 2007). One 
potential drawback of strategies involving agonists or partial agonists is the uncertainty of 
either receptor activation or desensitization, or both (Buisson and Bertrand, 2001; Lester et 
al., 2004). The lynx family proteins appear to increase the rate of desensitization of 
nAChRs (Ibanez-Tallon et al., 2004; Tekinay et al., 2009), and their removal results in 
nAChRs exhibiting less receptor desensitization. Therefore, inhibition of the endogenous 
action of lynx proteins may achieve the possibly desirable effect of increasing cholinergic 
tone while reducing desensitization. The majority of attention in pharmaceutical 
development is directed towards actions of compounds acting on receptors on the PM. Our 
data suggest that it may be important to consider intracellular mechanisms of action as 
well.  
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Chapter III: 
The β2V287L mutation suppresses formation of the lower 
sensitivity stoichiometry of α4β2 and increases α5α4β2 on the 
plasma membrane* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This chapter will be submitted as a manuscript to Molecular Pharmacology by the authors 
Weston A. Nichols, Brandon J. Henderson, Caroline Y. Yu, Chris B. Marotta, Christopher 
I. Richards, Bruce N. Cohen, and Henry A. Lester. 
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Abstract 
 
A number of mutations in α4β2-containing (α4β2*) nicotinic acetylcholine (ACh) receptors 
(nAChRs) are linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). 
Several increase the sensitivity, and reduce allosteric Ca2+ potentiation, of the α4β2 ACh 
response. Two α4β2 subtypes, with different subunit stoichiometries (α4)2(β2)3 and 
(α4)3(β2)2, exist in the cortex, along with α5α4β2 nAChRs. Previous results suggest that a 
knock-in mouse bearing the ADNFLE mutation β2V287L displays little functional 
expression of the (α4)3(β2)2 subtype. However, this hypothesis has not been tested using 
heterologously expressed receptors. We measured the effects of the β2V287L mutation on 
α4β2 and α5α4β2 nAChRs expressed in oocytes and mammalian cell lines using 
electrophysiological techniques, a voltage-sensitive fluorescent dye, and TIRF imaging of 
superecliptic pHlourin (SEP) tagged constructs. In oocytes, β2V287L reduced EC50 values 
for the high-senstitivity, (α4)2(β2)3, and low-sensitivity, (α4)3(β2)2, nAChRs by a similar 
factor and suppressed functional, low-sensitivity receptor plasma membrane (PM) 
expression. However, it did not affect the EC50 of α5α4β2 nAChRs. In mammalian cells, 
measurements of the α4β2 ACh response using a voltage-sensitive fluorescent dye and 
whole-cell patch-clamping demonstrated that while β2V287L reduced the overall α4β2 
maximum response, it increased the α4β2 response to sub-saturating ACh (1-10 µM). 
Imaging of SEP-tagged α5, α4, β2, and β2V287L subunits demonstrated that β2V287L 
reduced total α4β2 nAChR PM expression, increased the mean number of β2 subunits per 
α4β2 nAChR on the PM, and increased the surface expression of α5* nAChRs. Thus, 
mutations linked to ADNFLE can have subtype-selective effects on α4β2 nAChRs. 
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Introduction 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is an inherited 
partial epilepsy linked to mutations in α2, α4, and β2 nicotinic acetylcholine (ACh) 
receptor (nAChR) subunits. Recent studies also link ADNFLE to mutations in a sodium-
gated potassium channel KCNT1 (Heron et al., 2012) and, possibly, the corticotrophin 
releasing hormone (CRH) (Sansoni et al., 2013).  ADNFLE patients display brief nocturnal 
seizures that occur primarily during slow-wave (SW) sleep and originate in the frontal lobe. 
Penetrance for the nicotinic ADNFLE mutations ranges from 29% to 100%  (Ferini-
Strambi et al., 2012). Patient seizures typically begin between five and fifteen years of age  
(Scheffer et al., 1995). This time frame coincides with a developmental shift in the focus of 
slow-wave activity during sleep from the posterior brain to the frontal lobe  (Kurth et al., 
2010). The resulting increase in synchronized firing in the frontal lobe during SW sleep 
may facilitate the onset of ADNFLE seizures at this particular developmental stage. The 
pathophysiology of ADNFLE is not understood. However, a number of the nicotinic 
mutations linked to ADNFLE increase the sensitivity of α4β2 nAChRs to the endogenous 
agonist ACh and reduce Ca2+ potentiation of the ACh response.   
The β2V287L mutation is one of several nicotinic mutations linked to ADNFLE. 
Nicotinic receptors consist of five subunits arranged around a central pore. The β2V287L 
mutation is located near the extracellular entrance to the narrow part of the pore at the 22’ 
position (where position 1’ is the amino-terminus of the M2 transmembrane domain). This 
mutation produces several changes in the functional properties of heterologously expressed 
α4β2 nAChRs, including a reduction in the apparent rate of agonist-induced 
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desensitization, an increase in agonist-induced steady-state desensitization, a reduction in 
single-channel conductance, an increase in ACh sensitivity, and a reduction in Ca2+ 
potentiation of the ACh response  (De Fusco et al., 2000; Rodrigues-Pinguet et al., 2003,  
2005). Electroencephalographic (EEG) recordings from transgenic mice with untargeted 
β2V287L transgene insertions show that the mice display epileptiform activity during bouts 
of increased delta activity (presumably corresponding to SW sleep). Silencing 
conditionally-expressed mutant β2V287L transgenes in adult mice does not prevent 
epileptiform activity, but silencing it during early development does, even though the 
mutant transgene is later expressed in the adult mouse. Thus, the developmental effects of 
the β2V287L mutation appear to be a key feature of ADNFLE epileptogenesis  (Manfredi 
et al., 2009).   
Knock-in mice with targeted β2V287L insertions display increased mortality 
(possibly because of unobserved epileptic seizures) and behavioral abnormalities but 
apparently not spontaneous epileptiform EEG activity. The behavioral abnormalities of 
these mice include reduced nocturnal running wheel activity, increased ambulatory activity, 
increased locomotor habituation, and decreased anxiety-related behavior  (Xu et al., 2011). 
The mice also display altered nicotine-induced behaviors such as an increased sensitivity to 
nicotine-induced seizure signs, novel nicotine-induced tonic forelimb and digit extension, 
enhanced sensitivity to nicotine-induced hypothermia, and enhanced sensitivity to nicotine-
induced Y-maze behaviors. The β2V287L mutation affects both the function and 
expression of α4β2* nAChRs in situ  (O'Neill et al., 2013). The mutation significantly 
reduces the overall amount of α4β2* nAChR protein (but not mRNA) expressed in the 
brain (as measured by cytisine-sensitive [125I]epibatidine and mAb270 binding), reduces 
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maximal ACh-induced 86Rb, [3H]dopamine (DA), and cortical [3H]GABA release from 
mouse brain synaptosomes  (O'Neill et al., 2013), and increases the sensitivity of ACh-
induced 86Rb, [3H]dopamine (DA), and [3H]GABA synaptosomal release. 
The α4 and β2 nicotinic subunits are capable of forming functional α4β2 
pentameric receptors with different subunit stoichiometries in heterologous expression 
systems  (Zwart and Vijverberg, 1998). The two most common stoichiometries are 
(α4)2(β2)3 and (α4)3(β2)2. The ACh sensitivity of (α4)2(β2)3 receptors is ~100 times higher 
than that of (α4)3(β2)2 receptors  (Moroni et al., 2006). Consistent with these data, the ACh 
concentration-response relations for α4β2*-mediated 86Rb synaptosomal efflux is biphasic  
(Gotti et al., 2008). Thus, both native α4β2* nAChRs as well as heterologously expressed 
α4β2 nAChRs appear to be capable of assembling into functional receptors with two 
alternate α4:β2 stoichiometries. Studies of mice with partial α4 and β2 gene deletions 
suggest that (α4)2(β2)3 receptors mediate high-sensitivity (HS) ACh-induced 86Rb release 
from cortical and thalamic synaptosomes, and (α4)3(β2)2 receptors mediate LS release  
(Gotti et al., 2008).   
In the knock-in mouse model, the β2V287L mutation significantly reduces the LS 
component of the ACh concentration-response relation for 86Rb efflux from cortical 
synaptosomes but does not significantly affect the amplitude of the HS component  
(O'Neill et al., 2013). Selective suppression of the LS component suggests that the 
β2V287L mutation may inhibit formation of the LS (α4)3(β2)2 expression. Selective LS 
suppression may also account for some previously reported effects of the ADNFLE 
mutations on the ACh concentration-response relation. However, the sole previous study of 
how ADNFLE mutations affect subunit stoichiometry of α4β2 nAChRs suggests that they, 
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in fact, increase the fraction of (α4)3(β2)2 (LS) receptors in the population  (Son et al., 
2009).   
We used two approaches to determine whether the β2V287L mutation affects the 
subunit stoichiometry, and ACh sensitivity, of α4β2 nAChRs expressed in oocytes and 
mammalian cell lines. The first approach was to bias HS and LS α4β2 expression by 
systematically varying ratio of α4:β2 cRNA injected into oocytes and measure the effects 
of the mutation on the ACh concentration-response relations of the expressed receptors.  
We also studied the effects of the mutation on α4β2 nAChRs expressed in mammalian cell 
lines using a fluorescent membrane potential assay and whole-cell patch clamp 
electrophysiology. The second approach was to tag α4, β2, α5, and β2V287L subunits with 
superecliptic pHlourin (SEP) and measure the effects of the mutation on expression of the 
tagged subunits in the endoplasmic reticulum (ER) and plasma membrane (PM) of a 
mammalian cell line  (Miesenbock et al., 1998). SEP is a pH-sensitive GFP analog that in 
fluorescent at in basic conditions, but quenched in acidic solution, with a pKa ~7.0. 
Perfusing cells with acidic extracellular solution quenches fluorescent PM proteins with 
extracellular SEP tags. Thus, surface α4-, β2-, and β2V287L-SEP subunit expression can 
be estimated by measuring the acid-induced reduction in total subunit fluorescence  
(Richards et al., 2011).   
The α5 nicotinic subunit co-assembles with α4 and β2 to form a high-sensitivity 
α5α4β2 nAChR  (Brown et al., 2007). To determine whether the β2V287L mutation alters 
the expression, and/or ACh sensitivity, of α5α4β2 nAChRs, we measured the effects of the 
mutation on the ACh concentration-response relations of α4β2 and α5α4β2 nAChRs 
expressed in both oocytes and mammalian cells, and on α5α4β2 surface expression using 
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SEP-tagged α5 subunits (α5-SEP). The results show that β2V287L increases the ACh 
sensitivity of both HS and LS α4β2 nAChRs, inhibits the formation of LS α4β2 nAChRs, 
and enhances α5α4β2 nAChR surface expression without affecting α5α4β2 ACh 
sensitivity.     
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Experimental Procedures 
 
Molecular Biology  
For mammalian cell expression, we used wild-type (WT) mouse α4, α5, and β2 
cDNA clones inserted into pCI-NEO vectors. To measure subunit expression in the PM, C-
terminal superecliptic pHluorin (SEP) tags were added to the α5 and β2 subunits using a 
previously described PCR protocol and primers that overlapped the C-terminals of the 
coding sequences  (Richards et al., 2011). The forward primer for the α5-SEP reaction was 
5’-ACATTGGAAACACAATTAAGATGAGTAAAGGAGAAGAACT-3’, and the 
reverse primer was 5’-CGGGCCCTCTAGATCNTCAGGTTATTTGTATAGTTCATCCA 
-3’.  The forward primer for the β2-SEP reaction was 5′-
ACTCAGCTCCCAGCTCCAAGATGAGTAAAGGAGAAGAACT-3′ and the reverse 
primer was 5′- GGAGCTGCAAATGAGAGACCTTATTTGTATAGTTCATCCA-3′.  
After reaction completion, the resulting PCR products were cloned into a vector containing 
either the α5 or β2 cDNA clone using Pfu-Turbo polymerase. The mouse α4-SEP was 
constructed previously using the same protocol  (Richards et al.). We used the QuikChange 
II XL site-directed mutagenesis kit with the forward primer 5′- 
CTGCTCATCTCCAAGATTCTGCCTCCCACCTCCCTCGACGTA-3′ and the reverse 
primer 5′-TACGTCGAGGGAGGTGGGAGGCAGAATCTTGGAGATGAGCAG-3′ to 
construct the β2V287L mutation. For oocyte expression, we used mouse nAChR α5, α4 
and β2 cDNA clones inserted into pGEMHE vectors. The QuikChange protocol 
(Stratagene) was used for site-directed mutagenesis. To make cRNAs for the oocyte 
injections, α4 and β2 cDNA plasmids were linearized using SbfI. The α5 plasmid was 
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linearized using SphI. Linearized DNA was purified (Qiagen) and cRNA was 
synthesized from it using the T7 mMessage Machine kit (Ambion). The Qiagen RNeasy 
RNA purification kit was used to purify synthesized cRNA. 
 
Tissue Culture and Transfection 
Mouse Neuro-2a (N2a) cells were cultured using standard techniques and 
maintained in DMEM supplemented with 10% FBS.  N2a cells were plated by adding 
90,000 cells to poly-d-lysine-coated 35-mm glass-bottom imaging dishes (MatTek Corp.). 
The day after plating, plasmid DNA was mixed with cationic lipids by adding 500-750 ng 
of each nAChR plasmid to 4 µl of Lipofectamine 2000 transfection reagent in 200 µl of 
DMEM. After 20 min at ambient temperature, the transfection mixture was added to N2a 
cells in 1 ml of plating medium and incubated at 37 °C for 24 h. Dishes were rinsed twice 
with plating medium and incubated at 37 °C for another 24 h before imaging or performing 
electrophysiological experiments.  
HEK cells were also cultured using standard cell techniques as detailed above. The 
cells were plated onto black-bottom 96-well plates at a density of 50,000 cells per well.  
The next day, they were transfected with 100 ng of the appropriate cDNA mixtures 
combined with 4 uL of Lipofectamine 2000, as described above. Transfected cells were 
used 24 h later for the fluorescent membrane potential assay.  
 
Fluorescent Membrane Potential Assay 
We used a fluorescent plate reader (FlexStation III, Molecular Devices, Sunnyvale, 
CA) and a proprietary voltage-sensitive dye to measure the ACh concentration-response 
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relations of nAChRs expressed in HEK cells. The cells were transiently transfected with 
nAChR subunits and plated in flat-bottom 96-well plates. One day after plating, ACh 
voltage responses were measured visually using the Membrane Potential Blue-Dye Kit 
(Molecular Devices, Sunnyvale, CA). ACh was added to the wells at a speed of 16 mL/sec.  
The peak response was used to construct the ACh concentration-response relations. 
 
Oocyte Injections and Electrophysiology 
We used a standard protocol approved by the Office of Laboratory Animal 
Research at the California Institute of Technology to surgically harvest Xenopus laevis 
stage V and VI oocytes. To express α4α5β2 nAChRs in the oocytes, α5, α4 and β2 mRNAs 
were mixed in a ratio of 10:1:1 (w/w/w) to produce a final concentration of 0.8 ng/nL. 
Individual oocytes were then injected with 50 nL of this mixture, to deliver a total of 40 ng 
of mRNA per oocyte. To express α4β2 nAChRs, α4 and β2 mRNAs were mixed in a ratio 
of 1:1 or 10:1 to produce final concentrations of 0.13 ng/nL or 0.42 ng/nL, respectively.  
The oocytes were injected with a total of 6.7 ng or 21 ng of mRNA, respectively (in 50 nL). 
After injection, the oocytes were incubated in ND96+ medium (96 mM NaCl, 2 mM KCl, 
1.8 mM CaCl2, 1.8 mM MgCl2, 5 mM HEPES, 2.5 mM Na pyruvate, 0.6 mM theophylline, 
50 mg/mL gentamycin, 5% horse serum, pH 7.4) at 18° C for 24-96 h. Acetylcholine 
chloride was purchased from Sigma-Aldrich and dissolved in a nominally Ca2+-free ND96 
buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES at pH 7.5). An automated 
two-electrode voltage-clamp (OpusXpress 6000A, Axon Instruments) was used to record 
ACh-induced currents from the injected oocytes at a holding potential of -60 mV.  Ca2+-
free ND96 was used as the recording saline. To measure the ACh response, ACh was 
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microperfused onto the oocytes for 15 seconds followed by a 2 min saline rinse. To 
generate the ACh concentration-response relations, we applied 18 different concentrations 
of ACh to a single oocyte. Data were low-passed filtered at 5 Hz prior and sampled 
digitally at 20 Hz.  
 
Whole-Cell Patch Clamping 
N2a cells were co-transfected with nicotinic subunits and GFP to facilitate visual 
identification of cells expressing nicotinic receptors. We used an inverted fluorescence 
microscope (IX71, Olympus) equipped with a high-pressure Hg lamp (HB-10103AF, 
Nikon) to visualize fluorescing cells. Whole-cell voltage-clamp currents were recorded 
using an Axopatch-1D amplifier (Axon Instruments) and digitized with a Digidata 1440A 
analog-to-digital converter (Axon Instruments) under the control of the pClamp 10.0 
software (Axon Instruments). The pipette-filling solution contained (in mM): 135 K 
gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP (pH was 
adjusted to 7.2 with Tris-base, osmolarity to 280-300 mOsm with sucrose). Patch electrode 
input resistance was 2-4 MΩ. All recordings were obtained at ambient temperature. The 
data were low-passed filtered at 2 kHz and sampled at 10 kHz. ACh was dissolved in an 
extracellular solution containing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 
and 10 glucose (320 mOsm, pH to 7.3 with Tris-base), and microperfused onto cells using 
either pressure ejection through a glass micropipette (0.3 s pulse of 20 psi) or a 
commercially available microperfusion system (Octaflow II, ALA Scientific Instruments). 
The holding potential was -50 mV.  To minimize agonist-induced desensitization, we 
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applied ACh at 3 min intervals, and continually perfused the recording chamber with 
saline.   
 
TIRF Microscopy 
Live N2a cells were imaged 24 h after transfection in a stage-mounted culture dish 
incubator at 37 °C (Warner Instruments). Total internal reflection fluorescence microscopy 
(TIRFM) allowed us to visualize fluorescently labeled intracellular molecules within 200 
nm of the cell-coverslip interface. TIRF images were obtained using an inverted 
microscope (IX81; Olympus) equipped with an Olympus PlanApo 100× 1.45 NA oil 
objective and a stepper motor (Thorlabs) to control the position of the fiber optic and TIRF 
evanescent field illumination. The microscope included a drift control module that 
maintained samples at a constant focus for periods of ≥24 h. Neuronal medium was 
exchanged for a simpler extracellular solution (ECS) (in mM: 150 NaCl, 4 KCl, 10 
HEPES, 2 MgCl2, 2 CaCl2, and 10  glucose, pH 5.4 or 7.4) prior to imaging. SEP was 
excited using the 488-nm line of a multiline air-cooled argon laser (IMA101040ALS; 
Melles Griot). Images were captured with a back-illuminated EMCCD camera (iXON DU-
897). Frame rates, laser power settings, and camera gain parameters were initially adjusted 
and maintained at a constant setting across all samples for each imaging session. We 
acidified the imaging dish by perfusing the bath (normally pH 7.4) with an otherwise 
identical solution adjusted to pH 5.4. The ratio of PM to ER expression was determined by 
taking an initial TIRF image of each cell at pH 7.4 followed by acidification of the solution 
and a subsequent low-pH image. A region of interest encompassing just the cell was 
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internally thresholded to specifically demarcate the ROI. The ratio of the average 
intensities (fluorescence at pH 5.5/initial fluorescence at pH 7.4) indicates the fraction of 
PM fluorescence; smaller values imply higher PM expression.  
Statistical Analysis 
Concentration-response relations for both membrane potential responses from the 
FlexStation and voltage measurements from electrophysiology were fit to the Hill equation 
using nonlinear least-squares regression (OriginLab software). Errors for the mean values 
reported in the text are ± SEM. SEMs for the ratios of two mean values were calculated 
using a previously published approximation  (Motulsky, 2010). Statistical significance was 
determined by Student’s t test.  Significant differences are reported at the level of p<0.05 
(*), p<0.01 (**), or p<0.001 (***). 
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Results 
 
β2V287L suppresses LS receptor expression in oocytes  
Previous results for the β2V287L knock-in mouse suggest that the β2V287L 
mutation selectively reduces the functional expression of LS α4β2* nAChRs in cortical 
synaptosomes  (O'Neill et al., 2013). This reduction could result from an inherent effect of 
the mutation on the assembly or degradation of LS receptors, or a systemic regulatory 
response to the mutated receptors that only occurs in vivo. To determine whether LS 
suppression was an inherent property of the β2V287L mutation, we injected oocytes with 
either α4β2 or α4β2V287L cRNAs in a 1:1 or 10:1 α:β ratio, and measured the ACh 
concentration-response relations of the expressed receptors.  Injecting oocytes with equal 
amounts of α4 and β2 cRNA yields a mixture of LS and HS α4β2 nAChRs,  injecting them 
with an excess of α4 cRNA favors the formation of LS nAChRs because LS receptors 
contain three α4 and only two β2 subunits (Zwart and Vijverberg; Moroni et al., 2006), and 
injecting them with an excess of β2 cRNA favors the formation of HS nAChRs because HS 
receptors contain more β2 than α4 subunits. 
As expected, injecting α4:β2 WT cRNAs in a 1:1 ratio produced a biphasic ACh 
concentration-response relation (Fig. 3-1C).  The data were fit adequately by the sum of 
two hyperbolic binding functions with EC50s differing by >tenfold (Table 1).  HS receptors 
accounted for 65 ± 2% of the maximum WT response (Table 1).  In contrast, injecting 
α4:β2V287L cRNAs in a 1:1 ratio produced a monophasic ACh concentration-response 
relation that was adequately fit by a single hyperbolic binding function (Fig. 3-1C), 
suggesting that the β2V287L mutation suppresses LS receptor expression.  The EC50 of  
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Figure 3-1. Electrophysiological experiments conducted on nAChR constructs expressed in 
Xenopus laevis oocytes. A-B. Representative traces at ACh concentrations eliciting maximal 
response. C-D. Dose response relations for a (C) 1:1 and (D) 10:1 injection ratio of α4:β2 
for both β2-wt and β2-V287L. The β2-V287L mutation biases assembly towards a higher 
sensitivity receptor, but is still able to form two distinct receptor populations in oocytes. E-
F. Sample traces for α5α4β2 injected at a 10:1:1 ratio at ACh doses eliciting maximal 
response for (E) β2-wt and (F) β2-V287L. G. Dose-response relations for α5α4β2 are not 
altered by the β2-V287L mutation, providing evidence that the mutation does not alter the 
ACh sensitivity of α5α4β2 receptors. Solid squares represent β2-wt, and open circles 
represent β2-V287L conditions. 
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the α4β2V287L mutant receptor was also significantly (P < 0.001) less than that for WT 
HS receptors (by a factor of sixfold, Table 1).  Thus, the β2V287L mutation both increases 
the ACh sensitivity of HS receptors and suppresses the expression of LS receptors.   
Also consistent with previous data (Zwart and Vijverberg; Moroni et al., 2006), 
injecting α4:β2 cRNAs in a 10:1 ratio shifted the WT ACh concentration-response relation 
rightward (Fig. 3-1D).  To estimate the percentage of HS receptors in this population, we fit 
the concentration-response relation to the sum of two hyperbolic binding functions by 
constraining the EC50s for the two components to the values obtained from fitting the α4β2 
1:1 data (Table 1). Under these constraints, the percent of HS receptors in the population 
was 7 ± 4% and the percent of LS receptors was 93 ± 4 % (Table 1). Thus, the WT 10:1 
ACh concentration-response relation was nearly monophasic.  In contrast to the WT, 
injecting α4:β2V287L cRNAs in a 10:1 ratio produced a pronounced biphasic ACh 
concentration-response relation (Fig. 3-1D).  We fit these data to the sum of two hyperbolic 
binding functions but constrained the EC50 for the HS component to the value obtained by 
fitting the α4:β2V287L 1:1 data to a single hyperbolic binding component (Table 1). Using 
this constraint, the mutant HS receptors accounted for 23 ± 3% of the maximum response, 
and the LS receptors for 77 ± 3% (Table 1). The percentage of mutant HS receptors for the 
10:1 injection ratio was significantly larger than the corresponding value for the WT (Table 
1). Similar to the effects of the β2V287L mutation on HS receptors, the β2V287L mutation 
significantly (P < 0.05) reduced the EC50 for the LS receptors by a factor of fivefold (Table 
1). Thus, the β2V287L mutation both inhibits functional LS expression in oocytes even 
when we use cRNA injection ratios strongly favoring LS expression and also increases the 
ACh sensitivities of both HS and LS α4β2 receptors by a similar factor.  
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α4β2, ACh, 
oocytes HS EC50 S.E.M. HS n S.E.M. LS EC50 S.E.M. LS n S.E.M. %HS 
β2wt 0.711 0.015 1.08 .017 143.2 15.0 1.93 0.295 67.4% 
β2VL 0.115 0.006 0.957 .042 
    
100.0% 
β2wt (10α:1β) 2.39 1.61 0.827 0.46 118.0 8.48 1.39 0.11 11.4% 
VL (10α:1β) 0.351 0.160 0.954 0.244 49.3 7.72 1.29 0.176 33.5% 
Table 3-1. A comparison of two-component Hill function equation fits to ACh dose-response relations 
in Xenopus oocytes injected with α4, and either β2-wt or β2-V287L cRNA. While the mutation results in 
only one HS population of receptor at a 1:1 injection ratio, it is possible to detect a LS population by 
biasing stoichiometry towards the LS with a 10α:1β ratio. These data suggest that the LS stoichiometry 
can form with the mutant β2VL subunit, but that it is heavily unfavored. Parameters correspond to 
ACh concentration-response relations in Figure 3-1C and D. The EC50 and Hill coefficient values 
represent the mean and SEM. The relative fractions of the high sensitivity component are included in 
the final column.  
 
α5α4β2, ACh, 
Oocytes EC50 S.E.M. n S.E.M 
β2-wt (10:1:1) 0.514 0.0379 1.026 0.0648 
β2-VL (10:1:1) 0.349 0.0081 1.181 0.0278 
Table 3-2. Single-component Hill function equation fits to 
α5α4β2 responses to ACh in Xenopus oocytes injected with α5, 
α4, and either β2-wt or β2-VL cRNA. No significant 
differences were found, indicating that incorporation of the β2-
VL subunit does not alter the sensitivity or Hill coefficient of 
the α5α4β2 receptor. 
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Previous results show that the α5 nicotinic subunit co-assembles with α4 and β2 
to form a highly ACh-sensitive nicotinic receptor  (Brown et al., 2007; (Kuryatov et al., 
2008). To determine whether the β2V287L mutation increased the ACh sensitivity of 
α5α4β2 nAChRs, we injected oocytes with α5, α4, and either β2-WT or β2-V287L cRNAs 
with a large excess of α5 (α5:α4:β2 ratio of 10:1:1) and measured the ACh concentration-
response relations of the expressed receptors (Fig. 3-1E, F, and G).  The WT and mutant 
ACh concentration-response relations of the expressed receptors were monophasic (Fig. 3-
1G), and fit adequately by single hyperbolic binding components with EC50s similar to 
those obtained for the mutant and WT α4β2 HS receptors (Table 3-1). The β2V287L 
mutation did not significantly affect the EC50 of α5α4β2 nAChRs (Table 3-2) even though 
it significantly reduced the EC50 of α4β2 nAChRs, suggesting that the mutation does not 
increase the ACh sensitivity of α5* nAChRs.  
 
β2V287L reduces the maximum α4β2 response in HEK cells 
The β2V287L mutation reduces the maximum agonist response of synaptosomal 
α4β2* nAChRs in mice  (O'Neill et al., 2013). To determine whether it had a similar effect 
on expressed α4β2 nAChRs, we transfected HEK cells with α4β2 (WT) or α4β2V287L 
(mutant) cDNAs and measured the responses of the expressed receptors to 5 and 300 µM 
ACh using a fluorescent membrane potential assay (Fig. 3-2). For the WT receptors, the 
peak amplitude of the 5 µM response was roughly half that of the 300 µM response (Fig. 3-
2a). In contrast, the peak amplitude of the mutant 5 µM response was not significantly 
different from that of the 300 µM response, suggesting that 5 µM is nearly a saturating 
concentration of ACh for the mutant receptors (Fig. 3-2a).  The response of the mutant
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Figure 3-2. Maximal responses at given concentrations and dose-repsonse relations were 
obtained using a FlexStation III membrane potential dye kit. Solid squares represent β2-wt, 
and open circles represent β2-V287L conditions. Statistics were performed with one-way 
ANOVA with post-hos Tukey test. * = p<0.05; **=p<0.01; ***=p<0.001. 
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ACh, 
HEK cells HS EC50 S.E.M. HS n S.E.M. LS EC50 S.E.M. LS n S.E.M. %HS 
α4β2-WT 1.72 0.24 1.05 0.13 91.27 28.2 0.69 0.16 58.0% 
α4β2V287L 0.45 0.081 0.65 0.09         100.0% 
α5α4β2-WT 1.58 0.17 1.35 0.161 85.12 19.8 1.16 0.282 39.9% 
α5α4β2V287L 0.636 0.106 0.888 0.129         100.0% 
Table 3-3. A comparison of two-component Hill function equation fits to ACh dose-response relations 
in HEK cells obtained using a FlexStation III and membrane potential dye kit. Cells were transfected 
with α4, and either β2-WT or β2V287L DNA at a 1:1 ratio, or α5, α4, and either β2 variant in a 1:1:1 
ratio. The β2V287L mutation results in loss of the LS component in mammalian cells when α5 is 
present or not. Parameters correspond to ACh concentration-response relations in Figure 3-2. The 
EC50 and Hill coefficient values represent the mean and standard error. The relative fractions of the 
high sensitivity component are included in the final column. 
 
receptors to 300 µM ACh was also ~40% smaller than the WT. Thus, β2V287L reduced 
the maximum ACh response of α4β2 nAChRs expressed in HEK cells by >50% and 
increased the overall sensitivity of the ACh response. These results are consistent with the 
mutant-induced reduction in the proportion of functionally expressed LS α4β2 nAChRs 
measured above in oocytes and show that a mutant-induced reduction in the maximum 
ACh response occurs in a mammalian expression system. 
We also measured full ACh concentration-response relations for HEK cells 
transiently transfected with α4β2 (1:1 ratio), α4β2V287L (1:1), α5α4β2(1:1:1), and 
α5α4β2V287L (1:1:1) cDNAs (Fig. 3-2). The data were fit to two-component Hill function 
equations (Table 3-3 and 3-4). The β2V287L mutation significantly reduced the EC50 and 
maximum response of the ACh concentration response relation relative to the WT control 
(Table 3-3).  Co-expression with α5 did not significantly affect the WT or mutant EC50s 
(Table 3-4).  The Hill coefficients of the four concentration-response relations were also 
not significantly different. Thus, consistent with the oocyte experiments, β2V287L 
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increased overall ACh sensitivity and reduced the maximum response of α4β2 nAChRs 
expessed in HEK cells.  
 
α5 co-expression produces an increase in the mutant response relative to the WT  
Previous results show that co-expression of the ADNFLE mutant α4S247F subunit 
with the WT β2 subunit in HEK cells does not produce functional nicotinic receptors unless 
an accessory nicotinic subunit such as α5 is added  (Kuryatov et al., 2008). Our results 
show that HEK cells express functional α4β2V287L receptors without the need for an 
additional accessory subunit but the maximum ACh response of these receptors is less than 
that of the WT (Fig. 3-2A). To determine whether α5 co-expression improves functional 
α4β2V287L expression relative to the WT, we transfected HEK cells with α5α4β2 or 
α5α4β2V287L cDNA and measured the responses of the expressed receptors to 5 and 300 
µM ACh using a fluorescent membrane potential assay. Similar to the α4β2 WT response, 
the peak responses of cells transfected with WT α5, α4, and β2 subunits (1:1:1 ratio) to 5 
µM ACh was > 50% smaller than the 300 mM ACh response (Fig. 3-2B). In contrast, the 
response of cells transfected with α5, α4, and β2V287L subunits (1:1:1) to 5 µM and 300 
µM ACh were not significantly different, again suggesting that 300 µM ACh is close to 
saturation for the mutant receptors. Consistent with previous results for α4S247F ADNFLE 
mutation, α5 co-expression appeared to increase the mutant 300 µM ACh response relative 
to the WT. To test whether this increase was significant, we compared the ratio of the 
mutant to WT 300 µM ACh response with, and without, α5 co-expression (Fig. 3-3). The 
ratio of the α5α4β2V287L to α5α4β2-WT at 300 µM ACh response (0.79 ± 0.05, n= 24 
wells) was significantly larger (p < 0.05) than that of the α4β2V287L to α4β2 response 
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(0.64 ± 0.05, n= 24 wells).  Thus, consistent with the previously reported effect of a α5 
co-expression on β2* nAChRs containing the α4S247F ADNFLE mutation, α5 
significantly increased the functional expression of α4β2V287L* nAChRs relative to the 
WT control. 
 
Figure 3-3. FlexStation membrane potential assay comparing the magnitude of response to 
ACh of receptors containing mutant β2V287L to β2-WT. The β2V287L mutation increases 
the change in membrane potential upon agonist addition to a greater degree in cells 
transfected with α5α4β2 than α4β2 at both 5 and 300 µM ACh, doses that activate the HS, 
and HS+LS, respectively. These data suggest that the β2V287L subunit increases the 
incorporation of α5 subunits into PM receptors.  
β2V287L reduces the EC50 and maximum response of α4β2 nAChRs in N2a cells  
To validate the results of the fluorescent membrane potential measurements, we measured 
the effects of the b2V287L mutation on the ACh concentration-response relations of α4β2 
and α4β2V287L nAChRs expressed in a different mammalian cell line (N2a cells), using 
whole-cell patch clamping. ACh was applied to the cells using a rapid microperfusion 
system to minimize agonist-induced desensitization. The voltage-clamp concentration-
response data were fit to three-parameter Hill equations (Fig. 3-4,E-F and Table 3-4). The 
β2V287L mutation shifted the overall ACh concentration-response relation to the left. The 
α4β2V287L EC50 was 0.4 ± 0.1 µM compared to 30 ± 20 µM for the α4β2-WT value. The 
  
82 
Hill coefficients for both the mutant (0.7 ± 0.2) and WT receptors (0.6 ± 0.1) were less 
than unity, suggesting receptor heterogeneity in both cases. Due to the limited number of 
ACh concentrations tested (8 and 9 for WT and mutant, respectively), a two-component fit 
may be a less meaningful analysis of these data in compared to those from HEK and 
oocytes experiments. The peak α4β2V287L response to 1 µM ACh (650 ± 230 pA, n = 9 
cells) was significantly greater (P < 0.05) than the α4β2 WT value (100 ± 20 pA, n = 8) 
(Fig. 3-5B) but the α4β2V287L maximum response (900 ± 240 pA, n = 9) was 
significantly (P < 0.05) less than the WT value (1800 ± 400 pA, n = 8) (Fig. 3-4H). In 
summary, β2V287L reduced the overall EC50 of the ACh concentration-response relation 
and the maximum response, and increased the amplitude of peak ACh response at 
concentrations near the foot of the WT concentration-response relation (1 µM). Thus, the 
mutation does not uniformly reduce the ACh response throughout the entire concentration-
response relation. 
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Figure 3-4. Electrophysiology was performed in N2a cells transiently transfected with α4-
eGFP and either β2-WT or β2V287L cDNA. A-D. Sample traces at varying doses. E-F. 
Dose-response relations show that β2V287L shifts the EC50 to the left. These data are 
consistent with a loss of the LS receptor population, but are limited by the low number of 
doses tested (8 for WT and 9 for the mutant). G. At 1 µM ACh, peak currents are 
significantly higher with mutant. H. However, at doses of ACh eliciting a maximal response, 
the mutant peak current is half that of the WT receptor. These data are consistent with the 
mutant causing increased sensitivity, selective loss of the LS population, and about half of 
the total amount of receptors on the PM.  
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α4β2, ACh, 
N2a HS EC50 S.E.M. HS n S.E.M. LS EC50 S.E.M. LS n S.E.M. %HS 
α4β2-WT 1.70 0.41 1.04 0.249 52.65 13.2 1.5 3.88 47.0% 
α4β2V287L 0.31 0.070 0.89 0.167 11.8 40.8 1.5 9.9 91.1% 
Table 3-4. A comparison of two-component Hill function equation fits to ACh dose-response relations 
in N2a cells transiently transfected with α4-eGFP and either β2-WT or β2V287L cDNA. These fits 
were performed on data displayed in Figure 3-4.  The parameters shown here are consistent with the 
β2V287L mutation causing a leftward shift in EC50, selective loss of the LS component, and resulting 
reduction of total PM receptors by half. However, these data should be interpreted with caution due to 
the low number of ACh concentrations over which the function is fitted.  
 
β2V287L reduces surface receptor expression and alters subunit stoichiometry    
The decrease in the maximum response and suppression of the LS component of 
ACh concentration-response relation suggest that β2V287L reduces the total number of 
α4β2 nAChRs expressed on the PM and alters their subunit stoichometry. However, 
mutant-induced changes in the single-channel conductance, agonist desensitization, and 
agonist efficacy of HS and LS mutant receptors could contribute to these two effects. We 
used SEP-tagged subunits to independently determine whether the β2V287L mutation 
affected the number and subunit stoichiometry of α4β2 receptors expressed on the PM.     
To ensure that α4 and β2 subunits expressed in the PM were incorporated into 
receptors, we asked whether individual α4 and β2 SEP-tagged subunits could be expressed 
on the cell surface without co-transfection of the complementary subunit (Fig. 3-5). We 
found that individual subunits, without the complementary subunit required to form a 
pentamer, did not reach the PM. Transfection with either WT α4-SEP or β2-SEP alone 
resulted in easily detectable fluorescent protein inside the cell but almost none on the 
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plasma membrane (Fig. 3-5B). Thus, in the absence of the complementary subunit, 
almost all α4 and β2 protein remains inside the cell in the ER. 
We then measured the effects of the β2V287L mutation on surface α4-SEP and β2-
SEP expression in cells transfected with both subunits (Fig. 3-6).  The β2V287L mutation 
significantly reduced the surface expression of both subunits. Surface fluorescence for the 
α4-SEP subunit of the mutant receptors was 36 ± 6 % (n = 54 cells) that of the WT 
receptors.  Surface fluorescence of the β2V287L-SEP subunit was 60 ± 8 % (n = 54) that of 
the WT β2 subunit. Thus, the mutation reduced the surface expression of both subunits but 
the fractional reduction in PM α4 subunits was more than that for β2. If the mutation 
simply reduced the number of surface receptors without altering their subunit 
stoichiometry, then the number of α4-SEP and β2V287L-SEP subunits in the mutant 
receptors would decline by the same percentage.  However, there was a significantly 
greater (P < 0.05) decrease in the percentage of α4-SEP on the cell surface than β2-SEP. 
Thus, the β2V287L mutation reduced both the total number of surface receptors and the 
mean number of α4 subunits incorporated into individual mutant surface receptors.   
We can estimate the mutant-induced reduction in total surface receptors and the 
proportion of HS receptors in the WT surface receptor population from the mutant-induced 
reductions in α4-SEP and β2-SEP surface expression by making two simplifying 
assumptions (depicted in Fig. 3-7). First, we assume that the α4β2 subunit ratio for the WT 
HS receptors is 2:3, and that for the LS receptors is 3:2. This assumption is consistent with 
previous studies  (Zwart and Vijverberg, 1998; Moroni et al., 2006). Second, we assume 
that mammalian cell lines transfected with equal amounts of α4 and β2V287L cDNA 
(w/w) express express only HS receptors in the plasma membrane, and their α:β subunit 
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Figure 3-5. Single SEP-tagged nAChR subunits do not reach the plasma membrane. A. 
Representative images of either α4-SEP and β2-SEP transiently transfected into N2a cells 
without the complementary subunit. B. Minimal quenching occurs upon perfusion with 
acidic extracellular solution, indicating a lack of SEP-containing single subunits on the PM. 
This control experiment demonstrates the ability of the SEP assay to detect PM populations 
of SEP tagged nAChR subunits. 
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Figure 3-6. The β2V287L mutation causes a ~60% decrease in PM levels of α4, and a ~60% 
decrease in β2. A and C. Representative images of N2a cells transiently transfected with an 
SEP-tagged subunit and the complementary subunit. B. The β2V287L mutation results in a 
decline in the amount of total α4-SEP, which is seen both on the plasma membrane and 
interior to the cell. D. The mutation results in a smaller decrease in the β2 population on the 
PM, and an increase in the amount of β2 inside the cell. These data are consistent with the 
hypothesis that the mutation inhibits the incorporation of the α4 subunit into the accessory 
position, possibly leading to an increased rate of degradation, which could account for the 
overall lower total level of a α4-SEP when co-transfected with the β2V287L mutant subunit.  
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Figure 3-7. Our model shows excellent agreement between predicted and experimental data, 
demonstrating that the β2V287L mutation results in loss of the lower sensitivity (LS) 
population of receptors on the PM, but does not affect levels of the higher sensitivity (HS) 
receptor on the PM. Upon loss of all LS receptors, and no change in HS number, a 60% 
decrease in α4-SEP, and a 40% decrease in β2-SEP is expected, which agrees with 
experimental data.  
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ratio is 2:3 (identical to WT HS receptors). Using these two assumptions, the number of 
surface WT α4 subunits (aWT) is: α!"=𝑇!"[2 𝑥 + 3 1− 𝑥 ], 
where TWT is the total number of α4β2 surface receptors, x is the fraction of HS receptors, 
2(x) is the number of a subunits in surface HS receptors, and 3(1-x) is the number in surface 
LS receptors.  The number of mutant surface α4 subunits (αM) is simply: 
 𝛼!=2𝑇!, 
where TM is the total number of mutant α4β2V287L surface receptors.  Taking the ratio of 
these two values (αM/αWT) and simplifying, we have: !!!!" = !!!!!"(!!!).                Eq. 1 
The number of surface WT β2 subunits (βWT) is: 𝛽!"=𝑇!"[3 𝑥 + 2 1− 𝑥 ]. 
The number of mutant surface β2V287L subunits (βM) is: 
 𝛽!=3𝑇!. 
Taking the ratio of βM to βWT and simplifying, we have: !!!!" = !!!!!!(!!!).                 Eq. 2 
Dividing αM/αWT by βMβbWT , we have: 
!!!!"!!!!" = !(!!!)!(!!!)                      Eq.3 
Solving Eq. 3 for x yields: 
𝑥 = !!!!!"!!"!!!!!!!!!"!!!!!!!!                        Eq. 4 
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Substituting the mean values for αM/αWT (0.36) and βM/βWT  (0.6) obtained above in Eq. 4 
gives a value of 0.37 for x.  Solving Eq. 2 for TM/TWT, we have: (!!!)! !!!!" = !!!!".                Eq. 5 
Substituting a value of 0.37 for x and 0.60 for βM/βWT in Eq. 2 gives a value of 0.47 for 
TM/TWT.  According to this analysis, the β2V287L mutation reduced the total number of 
α4β2 nAChRs expressed on the plasma membrane of HEK cells by 53% ((1-0.47) X 100) 
and HS receptors account for 37% of the WT α4β2 nAChRs expressed in the plasma 
membrane of HEK cells. Thus, the β2V287L mutation reduces surface receptor expression 
and alters the subunit stoichiometry of these receptors. 
 
The β2V287L Mutation increases α5 surface expression 
The fluorescent membrane potential data suggest that α5 increases the number of 
α4β2V287L* mutant nAChRs expressed on the cell surface (Fig. 3-2B & 3-3). To test this 
hypothesis, we co-expressed α5-SEP with α4 and either β2-WT or β2V287L in N2a cells 
and measured the total, internal, and PM α5-SEP fluorescence (Fig. 3-8). Co-expression 
with α4 and β2V287L subunits increased α5-SEP PM fluorescence nearly fourfold 
compared to co-expression with the α4 and β2-WT subunits. However, it did not 
significantly affect internal α5-SEP fluorescence. The increase in total fluorescence was 
due largely to the effect of the mutation on PM fluorescence. Thus, β2V287L enhances the 
incorporation of α5 into α4β2* surface nAChRs. This effect may explain the relative 
increase in the maximal ACh response of mutant α5α4β2V287L receptors compared to the 
WT α5α4β2 receptors (Fig 3-3 and Fig. 3-2B). 
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Figure 3-8.  The β2V287L mutation increases plasma membrane expression of α5. A. 
Representative images of N2a cells transfected with α5-SEP, α4, and either β2-WT or 
β2V287L cDNA at pH 7.4 and 5.5. B. The β2V287L  mutation caused an increase in both 
the total and PM fluorescence of α5-SEP, but not a significant change in the level of α5-SEP 
inside the cell. 
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Discussion 
Our main findings are that the β2V287L ADNFLE mutation reduces the proportion 
of LS α4β2 nAChRs expressed in the PM but increases the ACh sensitivities of both the 
HS and LS α4β2 nAChRs. These changes produce a leftward shift in the overall α4β2 ACh 
concentration-response relation and a reduction in the maximum response.  Despite 
reducing the maximum response, the β2V287L mutation actually increases the size of the 
voltage-clamped ACh response to a sub-saturating ACh concentration (1 µM). Previous 
experiments on mice with partial genetic deletions of the α4 or β2 nicotinic subunits show 
that HS and LS α4β2 nAChRs are expressed in vivo  (Gotti et al., 2008). In mice, β2V287L 
increases the ACh sensitivities of both HS and LS α4β2* nAChRs in brain synaptosomes 
and suppresses the functional expression of α4β2* LS receptors  (O'Neill et al., 2013). Our 
data show that the effects of the β2V287L mutation on α4β2* nAChRs in situ can be 
replicated with heterologously expressed receptors. Thus, they appear to be caused by a 
direct effect of the mutation on the assembly and function of α4β2 nAChRs rather than by 
system-level changes in the regulation of α4β2 receptor expression.    
The use of SEP-tagged subunits is a novel approach that allows us to study the 
effects of ADNFLE mutations on the PM expression and subunit stoichiometry of nicotinic 
receptors without relying on functional data. Results from the SEP experiments 
independently confirm three important conclusions of the electrophysiological and 
fluorescent membrane potential experiments. First, β2V287L reduces the total number of 
α4β2 nAChRs expressed in the PM. A previous PET study of ADNFLE patients with the 
α4S284F and β2V287L mutations shows that these mutations also reduce nAChR density 
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in the right dorsolateral prefrontal cortex  (Picard et al., 2006). Second, β2V287L reduces 
the mean number of β2 subunits per receptor (which is consistent with a reduction in the 
proportion of LS receptors in the population). Finally, SEP data show that β2V287L 
increases the number of α5 subunits in the PM of cells transfected with α5, α4, and β2 
subunits, suggesting that the mutation increases α5α4β2 nAChR surface expression.   
The sole previous study of how ADNFLE mutations affect the subunit 
stoichiometry of α4β2 nAChRs suggests that they increase the proportion of (α4)3(β2)2 
(LS) receptors in the population  (Son et al., 2009). This conclusion is based on Forster 
resonance energy transfer (FRET) measurements between combinations of GFP and 
mCherry tagged α4 and β2 subunits. A possible reason for the apparent discrepancy 
between these previous data and our SEP data is that the previous FRET experiments 
measure apparent changes in stoichiometry for all subunits, including those expressed 
inside the cell rather than exclusively on in the PM. Our SEP data provide a more direct 
measurement of changes in amounts of subunit proteins expressed on the cell surface than 
the FRET measurements conducted previously. Moreover, the SEP data are consistent with 
the functional data from Xenopus oocytes and two types of mammalian cell lines, HEK and 
N2a. These data, taken together, provide strongly support the conclusion that the β2V287L 
mutation suppresses the surface expression of LS α4β2 nAChRs. 
Similar to the α4S247F ADNFLE mutation  (Kuryatov et al., 2008), co-expression 
of WT α4 and mutant β2V287L subunits with the α5 subunit improves surface expression 
of the mutant receptor relative to the α5α4β2-WT. An α4 subunit is thought to occupy the 
accessory subunit position in the LS α4β2 pentamer. In contrast, β2 and α5 subunits occupy 
comparable positions in the HS α4β2 nAChR and α5α4β2 nAChR, respectively. Thus, 
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β2V287L-mediated suppression of LS expression suggests that the mutation inhibits the 
inclusion of α4 subunits in the accessory position. The predicted in vivo effects of the 
mutation are a loss of LS α4β2 nAChRs in the mutant mouse, but a sparing (or even an 
increase) of α5α4β2. In contrast to its effect on α4β2 nAChRs, the mutation does not 
appear to affect the ACh sensitivity of α5α4β2 receptors.      
Two previously reported effects of the ADNFLE mutations may result from LS 
suppression—reduced Ca2+ potentiation of the α4β2 ACh response and an increase in the 
Hill coefficient for the α4β2 ACh concentration-response relation. If Ca2+ potentiates the 
response of HS receptors less than it does LS receptors, then suppressing LS expression 
would be expected to reduce Ca2+ potentiation of the overall α4β2 ACh response, 
particularly in the upper range of the concentration-response relation where the HS 
response dominates.  Thus, reduced Ca2+ potentiation may be a consequence of reduced LS 
α4β2 expression. The previously reported increase in the Hill coefficients of the 
α4S248Fβ2 and α4(777ins3)β2 ACh concentration-response relations relative to WT 
control may also be a consequence of LS suppression  (Figl et al., 1998). We would expect 
LS suppression to increase the homogeneity of the receptor population and, thus, increase 
the Hill coefficient of the overall ACh concentration-response relation.   
Despite strong genetic evidence linking α4 and β2 nicotinic subunit mutations to 
ADNFLE, the pathophysiology of the disease is still poorly understood. Previous 
experiments using conditionally-expressed transgenic β2V287L mouse models suggest that 
alterations in brain development, rather than acute activation of the mutant receptors, evoke 
seizure activity  (Manfredi et al., 2009). Silencing the β2V287L mutant transgene during 
early development prevents the occurrence of seizures in adult mice despite expression of 
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the mutant transgene in the adult  (Manfredi et al., 2009). Thus, inactivating the 
conditionally expressed mutant transgene during early development suffices to prevent the 
onset of seizures in the adult. In contrast, silencing the transgene in adult mice does not 
prevent seizure activity. Previous studies of brain development show that β2* nAChRs 
regulate the development of excitatory synaptic transmission in the cortex  (Ballesteros-
Yáñez et al., 2010; (Lozada et al., 2012). Genetic deletion of the β2 subunit reduces 
dendritic spine density in pyramidal neurons in the prelimbic/infralimbic area  (Ballesteros-
Yáñez et al., 2010) and causes a redistribution of glutamatergic synapses from dendritic 
spines to the dendritic shaft in pyramidal neurons. In contrast, the activation of β2* 
nAChRs by nicotine during early development increases spine formation in the dendrites of 
pyramidal neurons  (Lozada et al., 2012). Our results show that β2V287L increases the 
response of α4β2 nAChRs expressed in HEK cells to sub-saturating ACh (1 µM), even 
though the mutation reduces the overall maximum ACh response. Thus, an increased 
mutant β2* nAChR response to sub-saturating ACh may enhance seizure susceptibility by 
altering the normal course of development for excitatory synaptic transmission in the brain.  
The suppression of LS α4β2 nAChR expression may contribute to ADNFLE 
epileptogenesis. The presence of both HS and LS α4β2 nAChRs in the same presynaptic 
nerve terminal would be expected to enhance the dynamic range of the presynaptic 
nicotinic response  (Harpsøe et al., 2011). Presynaptic nAChRs on cholinergic nerve 
terminals in the cortex act as autoreceptors that facilitate ACh release  (Ochoa and O'Shea, 
1994; (Quirion et al., 1994). In the absence of LS receptors, the response of these receptors 
may quickly saturate as the firing frequency of presynaptic cholinergic neurons escalates.  
Consequently, the loss of presynaptic LS nAChRs may limit the ability of ACh release 
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from cholinergic neurons to follow high-frequency stimulation. ACh release in the cortex 
can inhibit firing in postsynaptic neurons by activating muscarinic receptors. Reducing the 
firing frequency at which this inhibitory muscarinic response saturates could be 
proepileptic because it impairs muscarinic-mediated inhibitory feedback in the brain and/or 
the development of inhibitory feedback networks.   
In conclusion, our results show that the β2V287L ADNFLE mutation increases the 
ACh sensitivities of both HS and LS α4β2, but not α5α4β2 nAChRs. It also suppresses LS 
α4β2 expression. LS suppression may be a common feature of the ADNFLE mutations and 
could potentially explain their previously reported effects on Ca2+ potentiation of the ACh 
response. Both these effects may contribute to ADNFLE epileptogenesis by altering the 
development of excitatory synaptic connections in the brain and/or impairing the ability of 
presynaptic nAChR autoreceptors to properly regulate cortical ACh release. 
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To develop novel therapies for CNS disorders, we need to invest in our 
understanding of the basic biology and molecular details underlying neuronal processes.  A 
systematic approach for the cholinergic system would be to attempt to characterize how 
ligands interact with their receptors at the biophysical level, which specific receptor 
subtypes they interact with, where those receptors are located subcellularly, on which 
neurons, how those neurons fit into larger circuits, and finally, how those circuits control 
behavior. Full characterization of these parameters will be challenging if not impossible in 
the near term due to experimental limitations. For example, we have limited tools to 
interrogate the expression levels of the two stoichiometries of α4β2. This thesis develops a 
novel method using SEP, which works in cell culture to corroborate the 
electrophysiological data, but may face challenges if attempted in vivo due to the presence 
of a wider variety of stochiometries including other subunits besides only α4 and β2.  
If full characterization is intractable, we need to develop targeted hypotheses, test 
them rigorously across multiple laboratory models, and eventually test them in humans. To 
develop these hypotheses, however, systematic experiments should be used when they can 
generate a foundation for stronger hypothesis formulation. For example, one challenging 
aspect of studying lynx is that we know at least eight family members exist (lynx1-8), but 
we do not have good data on which lynx members bind to which nAChR subunits, and 
what the effect of binding may be on gating, desensitization, upregulation, or stoichiometry 
shifts. For some nAChR subunits that can be reliably expressed in heterologous expression 
systems, these experiments should be straightforward. For others, where expression is less 
reliable (i.e. α6), or harder to interpret (i.e. α5 incorporation into α4β2), it may be more 
difficult. While understanding the details of which lynx members bind to which nAChR 
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subtypes may not generate immediately exciting data, I expect these kinds of 
experiments to provide a solid foundation for further reaching hypotheses.  
Armed with the knowledge of which lynx members bind specific nAChR subtypes, 
we could compare the overlap of expression of mRNA or protein across different types on 
neurons and in different locations and circuits. Single-cell mRNA quantification techniques 
exist, and could be used to possibly describe this overlap at the single cell level, which 
could lead to insights about which types actually interact in vivo. The next step would be to 
disrupt this interaction, which might be accomplished several ways, including using a small 
molecule or cell-permeable cyclic peptide to prevent the binding of lynx to the nAChR or 
subunit, knocking down lynx expression with anti-sense oligonucleotides (ASOs) or 
siRNA, increasing lynx expression via mRNA delivery, or using cell-impermeable proteins 
such as antibodies to disrupt lynx binding only at the plasma membrane without changing 
its intracellular effects.  
Each of these methods will face unique challenges to implement. It is likely that 
advances in medicinal chemistry will be required for small molecule and cyclic peptide 
strategies, and advances in polymer science for ASO, siRNA, or mRNA drug delivery. 
Importantly, genetic knockout mice, which have already been made and characterized in 
several behavioral tests (Ibanez-Tallon et al., 2002; Miwa et al., 2006; Morishita et al., 
2010), will continue to be a productive tool. Conditional knockouts will be important to 
retain the effects of lynx proteins through development, as there is evidence that it acts as a 
developmental switch, and to remove it from neural systems later as an initial proof of 
concept for pharmacological inhibition.  
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Optogenetics is a powerful technology that allows for precise localization and 
control over channel opening, which will lead to insights about circuit wiring and how to 
control behaviors at a molecular level.  Although it will be challenging to implement in a 
patient, some are trying. More conventional methods may be more tractable in the short 
term, but an understanding of how circuits control behavior from optogenetics experiments 
will likely provide critical information to design those molecular therapies.  
The specific work in this thesis on leads to multiple insights that deserve further 
experimental investigation. It has been clear for over a decade that two stoichiometries of 
α4β2 exist, and while there have been doubts as to whether both form in vivo, both 
stoichiometries are present in synaptosomes derived from brain tissue (Gotti et al., 2008). 
Several papers have shown that the β2VL mutation results in increased sensitivity of the 
receptor, and I show in this thesis that a shift in stoichiometry could be part of the 
molecular underpinning through both a shift in stoichiometry and greater incorporation of 
α5. It remains a mystery why the increased sensitivity, or selective loss of the low 
sensitivity component would lead to ADNFLE.    
Based on the work in this thesis, the most plausible mechanism is that the β2VL 
mutation could drive greater incorporation of α5 into the α5α4β2 nAChRs, particularly in 
the cortex, where all necessary subunits are present and where ADNFLE seizures originate. 
Because α5-containing nAChRs have a higher permeability to calcium, and are thought to 
be responsible for increased long-range connectivity towards the outer layers of the cortex 
(Heath et al., 2010), the VL mutation could influence the development of α5-expressing 
neurons in the cortex, leading to hyperconnectivity and hypersynchrony, and ADNFLE. 
This hypothesis could be tested by crossing two existing mouse lines: the β2VL knock-in 
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with the α5 knockout mouse, and testing the crossed mice for both the behavioral 
abnormalities associated with b2VL mutation as well as taking brain sections to examine 
differences between the branching and length of neurons originating in the deep layers of 
the cortex. In the β2VL knockin/α5-KO mouse, I might also expect to find increased 
dendritic spines on those neurons. All of these hypotheses could be tested effectively by 
sectioning brain tissue and imaging via confocal microscopy. Finally, it would also be 
interesting to test the hypothesis that the α5 and β2VL containing nAChRs are more 
calcium permeable than α5α4β2-wt or α4β2-VL receptors. This would not only offer a 
plausible mechanism by which the mutation could cause ADNFLE, but also provide 
support for the hypothesis that increased intracellular calcium over the developmental 
period could lead to increased connectivity and chronic seizures.   
Another line of experimentation that was not addressed here is the possibility that 
lynx1 could influence the sub-cellular localization of nAChRs. The GPI-anchor of lynx1 
may interact with cholesterol rich lipid domains in the plasma membrane, thus controlling 
localization to synaptic, or perisynaptic regions by slowing diffusion through those regions. 
This hypothesis might be tested by labeling plasma membrane nAChRs with fluorescent 
particles that could be tracked at the single molecule level, such as quantum dots. I 
conducted several pilot experiments towards this goal, first labeling α7 with a quantum dot 
by first treating with biotinylatied α-bungarotoxin, then adding a streptavidin-conjugated 
quantum dot. I was able to label single α7 receptors, track them using custom tracking 
software, and calculate the mean square displacement (MSD) for each particle. 
Furthermore, removing cholesterol from the membrane with MB@@CD resulted in greater 
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diffusion as measured by MSD. This work was not pursued further in favor of the 
experiments in previous chapters.  
I believe following up on these initial results could be promising, although 
challenges of adding or removing lynx1 remain. The initial pilot experiments were 
conducted on mouse day E16.5 cortical neurons isolated and re-plated in tissue culture 
dishes. The lynxKO mouse could serve as a source of lynx-free neurons as a control. 
However, there is uncertainty surrounding the expression of lynx1 by neurons from wild-
type  mice. We know that α7 is not expressed immediately upon plating cortical neurons; it 
takes 2-3 weeks to reach an expression level of α7 on the plasma membrane high enough to 
be detected by staining with α-bungarotoxin-AlexaFluor conjugates. Expression levels of 
lynx1 may be more variable from cell to cell, and will be more difficult to detect. As far as 
I know, currently there is now way to detect lynx1 via a fluorescent marker such as an 
AlexaFluor conjugate because there is no reliable source of specific antibody to lynx1 of 
which I am aware. Some antibodies may work for western blots, but there may not be 
enough sample from mouse cortical preparations to harvest enough protein. Even if enough 
protein were available, concerns about cell-to-cell variability in a tissue culture dish would 
make interpretation of plus/minus lynx experiments challenging in my opinion.  
One solution is to make knock-in mice using the fluorescently tagged GFP-lynx1, 
mCherry-lynx1, and SEP-lynx1 constructs that I developed. Using these tools, we could 
harvest the same mouse cortical neurons and know which cells are expressing lynx1 in 
culture, and even in vivo by taking brain slices and performing confocal imaging 
experiments. Before investing the time and resources to create knock-in mice, it may be 
advisable to conduct a more thorough comparison of the fluorescently tagged lynx1 
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variants to wild-type lynx1. Although I saw very similar results with the two types of 
lynx1, in my opinion, the magnitude of the investment in a knock-in mouse warrants 
additional characterization across multiple models.  
Alternatively, as I have shown that lynx1 interacts with the α4 nAChR subunit in 
the ER, the GPI-anchor could be important in segregating either individual subunits or fully 
assembled pentamers to specific regions of the ER for export to the plasma membrane, 
export to specific compartments of the plasma membrane, or possibly retention in the ER. 
GPI-anchored proteins have been reported to be directly targeted to the apical domain of 
cells (Paladino et al., 2006), or the axons of neurons. To my knowledge, this thesis contains 
the first data to demonstrate the binding of a GPI-anchored protein to influence the 
assembly of a multi-subunit complex in the ER. The possibility that a GPI-anchored protein 
may also exert influence by regulating the trafficking of its binding partners would be both 
novel and highly interesting.  
Pharmacological manipulation of lynx1 provides a novel and interesting way to 
indirectly target nAChRs, potentially gaining greater specificity than direct modulation of 
the receptor. Many more experiments are necessary to understand the molecular 
interactions and the biological importance of interactions between lynx family members 
and nAChRs. Both systematic, exploratory, hypothesis-generating experiments, in addition 
to targeted and rigorous experiments designed to test hypothesis of high biological 
importance should be conducted to move the field forward. A greater understanding the 
biology of nAChRs is likely to lead to critical insights about neuroscience and better 
treatments for a wide range of CNS disorders including addiction, and cognitive and 
psychiatric disorders. 
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